<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="iso-abbrev">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="publisher-id">nar</journal-id>
    <journal-title-group>
      <journal-title>Nucleic Acids Research</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">0305-1048</issn>
    <issn pub-type="epub">1362-4962</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10767912</article-id>
    <article-id pub-id-type="pmid">37889037</article-id>
    <article-id pub-id-type="doi">10.1093/nar/gkad806</article-id>
    <article-id pub-id-type="publisher-id">gkad806</article-id>
    <article-categories>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI00010</subject>
      </subj-group>
      <subj-group subj-group-type="heading">
        <subject>Database Issue</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>SLKB: synthetic lethality knowledge base</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9238-1650</contrib-id>
        <name>
          <surname>Gökbağ</surname>
          <given-names>Birkan</given-names>
        </name>
        <aff><institution>Department of Biomedical Informatics, College of Medicine, The Ohio State University</institution>, <addr-line>Columbus</addr-line>, <addr-line>OH</addr-line> 43210, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Tang</surname>
          <given-names>Shan</given-names>
        </name>
        <aff><institution>College of Pharmacy, The Ohio State University</institution>, <addr-line>Columbus</addr-line>, <addr-line>OH</addr-line> 43210, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0392-1177</contrib-id>
        <name>
          <surname>Fan</surname>
          <given-names>Kunjie</given-names>
        </name>
        <aff><institution>Department of Biomedical Informatics, College of Medicine, The Ohio State University</institution>, <addr-line>Columbus</addr-line>, <addr-line>OH</addr-line> 43210, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6336-5416</contrib-id>
        <name>
          <surname>Cheng</surname>
          <given-names>Lijun</given-names>
        </name>
        <aff><institution>Department of Biomedical Informatics, College of Medicine, The Ohio State University</institution>, <addr-line>Columbus</addr-line>, <addr-line>OH</addr-line> 43210, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Yu</surname>
          <given-names>Lianbo</given-names>
        </name>
        <aff><institution>Department of Biomedical Informatics, College of Medicine, The Ohio State University</institution>, <addr-line>Columbus</addr-line>, <addr-line>OH</addr-line> 43210, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zhao</surname>
          <given-names>Yue</given-names>
        </name>
        <aff><institution>Department of Computational Medicine and Bioinformatics, College of Medicine, University of Michigan</institution>, <addr-line>Ann Arbor</addr-line>, <addr-line>MI</addr-line> 48104, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0746-1809</contrib-id>
        <name>
          <surname>Li</surname>
          <given-names>Lang</given-names>
        </name>
        <!--lang.li@osumc.edu-->
        <aff><institution>Department of Biomedical Informatics, College of Medicine, The Ohio State University</institution>, <addr-line>Columbus</addr-line>, <addr-line>OH</addr-line> 43210, <country country="US">USA</country></aff>
        <xref rid="COR1" ref-type="corresp"/>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="COR1">To whom correspondence should be addressed. Email: <email>lang.li@osumc.edu</email></corresp>
    </author-notes>
    <pub-date pub-type="collection">
      <day>05</day>
      <month>1</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2023-10-27">
      <day>27</day>
      <month>10</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>27</day>
      <month>10</month>
      <year>2023</year>
    </pub-date>
    <volume>52</volume>
    <issue>D1</issue>
    <fpage>D1418</fpage>
    <lpage>D1428</lpage>
    <history>
      <date date-type="accepted">
        <day>27</day>
        <month>9</month>
        <year>2023</year>
      </date>
      <date date-type="rev-recd">
        <day>16</day>
        <month>8</month>
        <year>2023</year>
      </date>
      <date date-type="received">
        <day>04</day>
        <month>6</month>
        <year>2023</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2023. Published by Oxford University Press on behalf of Nucleic Acids Research.</copyright-statement>
      <copyright-year>2024</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact <email>journals.permissions@oup.com</email></license-p>
      </license>
    </permissions>
    <self-uri xlink:href="gkad806.pdf"/>
    <abstract>
      <title>Abstract</title>
      <p>Emerging CRISPR–Cas9 technology permits synthetic lethality (SL) screening of large number of gene pairs from gene combination double knockout (CDKO) experiments. However, the poor integration and annotation of CDKO SL data in current SL databases limit their utility, and diverse methods of calculating SL scores prohibit their comparison. To overcome these shortcomings, we have developed SL knowledge base (SLKB) that incorporates data of 11 CDKO experiments in 22 cell lines, 16,059 SL gene pairs and 264,424 non-SL gene pairs. Additionally, within SLKB, we have implemented five SL calculation methods: median score with and without background control normalization (Median-B/NB), sgRNA-derived score (sgRNA-B/NB), Horlbeck score, GEMINI score and MAGeCK score. The five scores have demonstrated a mere 1.21% overlap among their top 10% SL gene pairs, reflecting high diversity. Users can browse SL networks and assess the impact of scoring methods using Venn diagrams. The SL network generated from all data in SLKB shows a greater likelihood of SL gene pair connectivity with other SL gene pairs than non-SL pairs. Comparison of SL networks between two cell lines demonstrated greater likelihood to share SL hub genes than SL gene pairs. SLKB website and pipeline can be freely accessed at <ext-link xlink:href="https://slkb.osubmi.org" ext-link-type="uri">https://slkb.osubmi.org</ext-link> and <ext-link xlink:href="https://slkb.docs.osubmi.org/" ext-link-type="uri">https://slkb.docs.osubmi.org/</ext-link>, respectively.</p>
    </abstract>
    <abstract abstract-type="graphical">
      <title>Graphical Abstract</title>
      <p>
        <fig position="float" id="ga1">
          <label>Graphical Abstract</label>
          <graphic xlink:href="gkad806figgra1" position="float"/>
        </fig>
      </p>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Ohio State University</institution>
            <institution-id institution-id-type="DOI">10.13039/100006928</institution-id>
          </institution-wrap>
        </funding-source>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="11"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="SEC1">
    <title>Introduction</title>
    <p>Synthetic lethality (SL) describes an interaction between two genes in which impaired function of both genes results in cell death, but compromised function of only one of the pair does not (<xref rid="B1" ref-type="bibr">1</xref>). The identification of SL can be highly impactful in the discovery of new drug therapies for catastrophic illnesses, such as cancer, as exemplified by the observation of SL interaction between <italic toggle="yes">PARP1</italic> and <italic toggle="yes">BRAC1</italic> genes (<xref rid="B2" ref-type="bibr">2</xref>) that led to the development of <italic toggle="yes">PARP1</italic> inhibitors for the treatment of patients with breast or ovarian cancer with <italic toggle="yes">BRCA1</italic> mutations. Such <italic toggle="yes">PARP1</italic> inhibitors approved by the US Food and Drug Administration include olaparib (2018), niraparib (2020) and talazoparib (2022) (<xref rid="B3" ref-type="bibr">3</xref>).</p>
    <p>Substantial work has been done in creating databases for SL interactions, and the SynLethDB has been a major resource in the integration of SL data (<xref rid="B4" ref-type="bibr">4</xref>). Its recent 2.0 version houses data for 35,943 SL pairs and 2,899 non-SL pairs in human cells. The SL pairs are integrated from <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in silico</italic> sources. The <italic toggle="yes">in vitro</italic> study sources comprise investigations of genome-wide RNAi, drug inhibition, external databases, i.e. DECIPHER and Syn-lethality (<xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B6" ref-type="bibr">6</xref>), CRISPR inference and high- and low-throughput studies. <italic toggle="yes">In silico</italic> studies, e.g. DAISY (<xref rid="B7" ref-type="bibr">7</xref>), examine SL prediction. In the SynLethDB, each SL pair is scored using the probability function, which is weighted from various data sources. CRISPR-inferred pairs have a high weight (0.85), and high-throughput screening-inferred pairs are scored the lowest (0.50).</p>
    <p>However, SynLethDB has several knowledge gaps, including inadequate coverage of combination gene double knockout (CDKO) experiments, especially those based in CRISPR–Cas9 technology, as well as incomplete or inaccurate cell-line annotations, and the database fails to differentiate the methods of calculating SL scores from CDKO experimental data. Although the literature includes 11 published CDKO experiments (Table <xref rid="tbl1" ref-type="table">1</xref>), which collectively report 16,059 SL pairs and 264,424 non-SL pairs, SynLethDB includes only 7,312 SL pairs and 2,899 non-SL pairs from five CDKO data sets, and does not report the criteria for their selection. Furthermore, incomplete cell-line annotation includes SynLethDB’s annotation of only SL data for HeLa cells from a report by Bartz and associates (<xref rid="B8" ref-type="bibr">8</xref>) that also reported SL genes in A549 and TOV21G cells. Inaccuracies include the annotation of MCF10A as BRCA by Wang and associates (<xref rid="B9" ref-type="bibr">9</xref>) and the annotation of A1847, A2780, C30, CP70, OVCAR5, SKOV3 and UPN275 as OV by Pathak's team (<xref rid="B10" ref-type="bibr">10</xref>). Additionally, in SynLethDB the differences in SL calculation methods are not considered. To address the challenges and knowledge gaps in the SynLethDB, we have developed synthetic lethality knowledge base (SLKB).</p>
    <table-wrap position="float" id="tbl1">
      <label>Table 1.</label>
      <caption>
        <p>Published gene combination double knockout experiments and synthetic lethality (SL) data</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th rowspan="1" colspan="1">Study</th>
            <th rowspan="1" colspan="1">Screening methods</th>
            <th rowspan="1" colspan="1">Study goal</th>
            <th rowspan="1" colspan="1">Cell line(s)</th>
            <th rowspan="1" colspan="1">Number of genes</th>
            <th rowspan="1" colspan="1">SL criteria</th>
            <th rowspan="1" colspan="1">SL data</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td rowspan="1" colspan="1">Wong <italic toggle="yes">et al.</italic> 2016 <italic toggle="yes">(</italic><xref rid="B18" ref-type="bibr">18</xref>)</td>
            <td rowspan="1" colspan="1">CombiGEM-CRISPR (combinatorial genetics en masse) (GeCKOv2 for control)</td>
            <td rowspan="1" colspan="1">identify combinatorial drug targets</td>
            <td rowspan="1" colspan="1">OVCAR8</td>
            <td rowspan="1" colspan="1">160 sgRNAs (3 controls), 23,409 dual sgRNAs, 50 genes, 1,225 gene pairs</td>
            <td rowspan="1" colspan="1">
              <bold>LFC &lt;−0.9, <italic toggle="yes">Q</italic>value &lt;0.01</bold>
            </td>
            <td rowspan="1" colspan="1">52 SL</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Han <italic toggle="yes">et al.</italic> 2017 (<xref rid="B19" ref-type="bibr">19</xref>)</td>
            <td rowspan="1" colspan="1">DrugTarget-CDKO</td>
            <td rowspan="1" colspan="1">generate human gene interaction map + identify combinatorial drug targets</td>
            <td rowspan="1" colspan="1">K562</td>
            <td rowspan="1" colspan="1">205 <bold>genes, 20,791 gene pairs</bold></td>
            <td rowspan="1" colspan="1">SL score &lt;−4</td>
            <td rowspan="1" colspan="1">40 SL</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Shen <italic toggle="yes">et al.</italic> 2017 (<xref rid="B20" ref-type="bibr">20</xref>)</td>
            <td rowspan="1" colspan="1">Combinatorial CRISPR–Cas9</td>
            <td rowspan="1" colspan="1">identify combinatorial drug targets</td>
            <td rowspan="1" colspan="1">HELA, 293T, A549</td>
            <td rowspan="1" colspan="1">266 <bold>sgRNAs, (47 controls), 74,724 dual sgRNAs, 73 genes, 2,628 gene pairs</bold></td>
            <td rowspan="1" colspan="1">SL score &lt;−3</td>
            <td rowspan="1" colspan="1">293T (59 SL), A549 (57 SL), HELA (52 SL)</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Horlbeck <italic toggle="yes">et al.</italic> 2018 (<xref rid="B14" ref-type="bibr">14</xref>)</td>
            <td rowspan="1" colspan="1">CRISPRi</td>
            <td rowspan="1" colspan="1">generate</td>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1">human gene interaction map</td>
            <td rowspan="1" colspan="1">Jurkat, K562</td>
            <td rowspan="1" colspan="1"><bold>1,023 sgRNAs, (18 controls)</bold>,<bold>1,693,897 sgRNAs</bold><bold>(2,088,968 initial), 458 genes (472 initial), up to</bold><bold>111,156 gene pairs</bold></td>
            <td rowspan="1" colspan="1">SL score &lt;−3</td>
            <td rowspan="1" colspan="1">JURKAT (374 SL), K562 (1523 SL)</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Najm <italic toggle="yes">et al.</italic> 2018 (<xref rid="B21" ref-type="bibr">21</xref>)</td>
            <td rowspan="1" colspan="1">Big <bold>Papi (paired aureus and pyogenes for interactions)</bold></td>
            <td rowspan="1" colspan="1">generate human gene interaction map</td>
            <td rowspan="1" colspan="1">876O, A375, A549, HT29, MELJUSO, OVCAR8</td>
            <td rowspan="1" colspan="1">192 <bold>sgRNAs, (42 controls), 52,296 dual sgRNAs, 25 genes, 300 gene pairs</bold></td>
            <td rowspan="1" colspan="1"><italic toggle="yes">Q</italic> value &lt;0.01</td>
            <td rowspan="1" colspan="1">A549 (2 SL), MELJUSO (4 SL), A375 (2 <bold>SL), HT29</bold></td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1">
              <bold>(3 SL), OVCAR8 (4 SL)</bold>
            </td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Zhao <italic toggle="yes">et al.</italic> 2018 (<xref rid="B16" ref-type="bibr">16</xref>)</td>
            <td rowspan="1" colspan="1">Combinatorial CRISPR–Cas9</td>
            <td rowspan="1" colspan="1">understanding metabolic pathways</td>
            <td rowspan="1" colspan="1">
              <bold>HELA, A549</bold>
            </td>
            <td rowspan="1" colspan="1">156 sgRNAs, <bold>23,868 dual sgRNAs, 51 genes, 1,275 gene pairs</bold></td>
            <td rowspan="1" colspan="1">SL score &lt;−3</td>
            <td rowspan="1" colspan="1">A549 (29 SL), HELA (27 SL)</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Ito <italic toggle="yes">et al.</italic> 2021 (<xref rid="B17" ref-type="bibr">17</xref>)</td>
            <td rowspan="1" colspan="1">Digenic CRISPR–Cas9</td>
            <td rowspan="1" colspan="1">understanding digenic dependencies</td>
            <td rowspan="1" colspan="1">HSC5, MeWo, MELJUSO, IPC298, HS936T, HS944T, PATU8988S, PK1, A549, GI1, MEL202</td>
            <td rowspan="1" colspan="1">
              <bold>19,706</bold>
              <bold>sgRNAs (2 controls), 1,219,614 dual sgRNAs, 3,284 genes, 4,859 gene pairs</bold>
            </td>
            <td rowspan="1" colspan="1">False discovery <bold>rate (FDR) &lt; 0.05</bold></td>
            <td rowspan="1" colspan="1">A549 (594 SL), GI1 (476 SL), HS936T (636 SL), HS944T (497 SL), HSC5 (705 SL), IPC298 (619 SL), MEL202 (688 SL), <bold>MELJUSO (547</bold></td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"><bold>SL)</bold>,</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1">MEWO (435 SL), PATU8988S</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1">(618 SL),</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1">PK1 (668 SL)</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Parrish <italic toggle="yes">et al.</italic> 2021 (<xref rid="B15" ref-type="bibr">15</xref>)</td>
            <td rowspan="1" colspan="1">
              <bold>pgPEN (paralog genetic interaction mapping, CRISPR)</bold>
            </td>
            <td rowspan="1" colspan="1">generate human paralog gene interaction map</td>
            <td rowspan="1" colspan="1">PC9, HELA</td>
            <td rowspan="1" colspan="1">9194 <bold>sgRNAs (975 control), 64,573 dual sgRNAs, 2,060 genes, 1,030 gene pairs</bold></td>
            <td rowspan="1" colspan="1">SL score <bold>&lt;−0.5, FDR &lt;0.1</bold></td>
            <td rowspan="1" colspan="1">PC9 (87 SL), HELA (70 SL)</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Diehl <italic toggle="yes">et al.</italic> 2021 (<xref rid="B22" ref-type="bibr">22</xref>)</td>
            <td rowspan="1" colspan="1">Covalently-closed circular-synthesized (3Cs) multiplexing, CRISPR</td>
            <td rowspan="1" colspan="1">understanding autophagy flux</td>
            <td rowspan="1" colspan="1">RPE1</td>
            <td rowspan="1" colspan="1">
              <bold>1,176 sgRNAs (188 controls), 248,191 dual sgRNAs, 200 genes, 10,720 gene pairs</bold>
            </td>
            <td rowspan="1" colspan="1">LFC &lt;−1</td>
            <td rowspan="1" colspan="1">
              <bold>6,776 SL</bold>
            </td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Thompson <italic toggle="yes">et al.</italic> 2021 (<xref rid="B23" ref-type="bibr">23</xref>)</td>
            <td rowspan="1" colspan="1">Combinatorial CRISPR–Cas9</td>
            <td rowspan="1" colspan="1">identify combinatorial drug targets</td>
            <td rowspan="1" colspan="1">
              <bold>A375, MEWO, RPE1</bold>
            </td>
            <td rowspan="1" colspan="1"><bold>13,310 sgRNAs (499 controls)</bold>,<bold>125,514 dual</bold><bold>sgRNAs, 1,680 genes, 1,192 gene pairs</bold></td>
            <td rowspan="1" colspan="1">FDR &lt;0.1</td>
            <td rowspan="1" colspan="1">A375 (44 SL), MEWO (40 SL), RPE (57 SL)</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Tang <italic toggle="yes">et al.</italic> 2022 (<xref rid="B11" ref-type="bibr">11</xref>)</td>
            <td rowspan="1" colspan="1">LentiGuide_DKO, LentiCRISPR_DKO (GeCKOv2 for control)</td>
            <td rowspan="1" colspan="1">identify combinatorial drug targets</td>
            <td rowspan="1" colspan="1">22Rv1</td>
            <td rowspan="1" colspan="1">247 <bold>sgRNAs (25 controls), 48,931 dual sgRNAs, 50 genes, 1,225 gene pairs</bold></td>
            <td rowspan="1" colspan="1">SL <bold>score &lt;−0.361</bold></td>
            <td rowspan="1" colspan="1">274 SL</td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
  </sec>
  <sec sec-type="materials|methods" id="SEC2">
    <title>Materials and methods</title>
    <sec id="SEC2-1">
      <title>Introduction of CRISPR-based gene CDKO experiment</title>
      <p>We recently published the technical details of the design and protocol of our CDKO experiment (<xref rid="B11" ref-type="bibr">11</xref>). Here, we focus on dual single-guided RNA (sgRNA) design and the corresponding data, in which a sgRNA targets either one gene or no gene, i.e. the control sgRNA. Without loss of generalizability, let us assume that the design includes <inline-formula><tex-math id="M0001" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$K$\end{document}</tex-math></inline-formula> control sgRNAs and <inline-formula><tex-math id="M0001a" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$M$\end{document}</tex-math></inline-formula> sgRNAs targeting a single gene. Figure <xref rid="F1" ref-type="fig">1A</xref> presents an overview of a CDKO synthetic lethal screen, in which cells were transfected with a dual-sgRNA library on Day 0. These dual-sgRNAs are sequenced at baseline and again after <italic toggle="yes">T</italic> days of cell culture. Figure <xref rid="F1" ref-type="fig">1B</xref> illustrates that there are <inline-formula><tex-math id="M0002" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$n = {K}^2$\end{document}</tex-math></inline-formula> control dual-sgRNAs. Figure <xref rid="F1" ref-type="fig">1C</xref> shows two types of dual sgRNA targeting one gene. In the first scenario, one control sgRNA and one sgRNA target a gene (<inline-formula><tex-math id="M0003" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$n = 2MK)$\end{document}</tex-math></inline-formula>, and in the second scenario, two sgRNAs target the same gene <inline-formula><tex-math id="M0004" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$( {n = {M}^2} )$\end{document}</tex-math></inline-formula>. Figure <xref rid="F1" ref-type="fig">1D</xref> shows dual sgRNAs targeting two genes. If we consider orientations, <inline-formula><tex-math id="M0005" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$n = 2{M}^2$\end{document}</tex-math></inline-formula> dual sgRNAs are targeting one gene pair.</p>
      <fig position="float" id="F1">
        <label>Figure 1.</label>
        <caption>
          <p>Overview of synthetic lethality (SL) library. <bold>(A)</bold> Design of SL combination gene double knockout (CDKO) experiment. <bold>(B)</bold> Control target sgRNA pairs. <bold>(C)</bold> Single-target sgRNA pairs. <bold>(D)</bold> Dual-target sgRNA pairs.</p>
        </caption>
        <graphic xlink:href="gkad806fig1" position="float"/>
      </fig>
    </sec>
    <sec id="SEC2-2">
      <title>Current CDKO experimental data and data processing methods</title>
      <p>We have identified 11 published CDKO experiments (Table <xref rid="tbl1" ref-type="table">1</xref>). Each study used unique methods of processing and analyzing data to calculate SL scores, thereby creating a significant barrier for comparison of the data. <xref rid="sup1" ref-type="supplementary-material">Supplementary Table S1</xref> summarizes the experiments according to the data processing steps—sgRNA sequencing data filtering, between-sample normalization, normalization on control sgRNAs—and the methods for calculating SL scores. We decided to construct a collection of SL scores based on these published methods, taking into consideration of the methods’ choice of data processing and methods of data analysis, allowing for preservation of some diversity and the retention of several well-established statistical models, such as GEMINI and MAGeCK (<xref rid="B12" ref-type="bibr">12</xref>,<xref rid="B13" ref-type="bibr">13</xref>). We did not attempt to regenerate data analysis methods that were inadequately detailed in the initial publication or shared with a computational software. The methods were evaluated across initial and final timepoint of experiments to lay common ground between calculations. Table <xref rid="tbl2" ref-type="table">2</xref> summarizes these five representative methods: Horlbeck (<xref rid="B14" ref-type="bibr">14</xref>), MAGeCK, GEMINI (<xref rid="B12" ref-type="bibr">12</xref>), median-background/no background (Median-B/NB) and sgRNA derived-background/no background (sgRNA-B/NB). The <xref rid="sup1" ref-type="supplementary-material">Supplementary File presents</xref> a more detailed technical description of these five methods.</p>
      <table-wrap position="float" id="tbl2">
        <label>Table 2.</label>
        <caption>
          <p>Methods of scoring synthetic lethality (SL)</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th rowspan="1" colspan="1">SL scoring approaches</th>
              <th rowspan="1" colspan="1">Filtering</th>
              <th rowspan="1" colspan="1">Normalization</th>
              <th rowspan="1" colspan="1">Processing</th>
              <th rowspan="1" colspan="1">SL calculation method</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">GEMINI score</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">sgRNA counts are normalized to the median of all time points.</td>
              <td rowspan="1" colspan="1">a pseudo-count of 32 is added after normalization.</td>
              <td rowspan="1" colspan="1">variational Bayes: using coordinate ascent variational inference on LFC</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">MAGeCK score</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">sgRNA counts are normalized to the median of all time points.</td>
              <td rowspan="1" colspan="1">a pseudo-count of 1 is added before normalization.</td>
              <td rowspan="1" colspan="1">difference between calculated MAGeCK-LFC and single gene MAGeCK-LFC</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Horlbeck score</td>
              <td rowspan="1" colspan="1">Filter sgRNAs with median counts &lt;35</td>
              <td rowspan="1" colspan="1">LFC is normalized to the count ratio between time points.</td>
              <td rowspan="1" colspan="1">a pseudo-count of 10 is added before normalization.</td>
              <td rowspan="1" colspan="1">difference between calculated LFC and quadratic fit of LFC</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Median with background control normalization (Median-B)</td>
              <td rowspan="1" colspan="1">Filter sgRNAs with counts &lt;35 at initial time point</td>
              <td rowspan="1" colspan="1">sgRNA counts are normalized to the median of final time points across single, control, and dual targeting sgRNAs.</td>
              <td rowspan="1" colspan="1">a pseudo-count of 10 is added before normalization.</td>
              <td rowspan="1" colspan="1">difference between calculated LFC and single gene LFCs, normalized to median LFC of controls</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Median without background control normalization (Median-NB)</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">difference between calculated LFC and single gene LFCs<break/></td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">sgRNA-derived SL with background control normalization (sgRNA-B)</td>
              <td rowspan="1" colspan="1">Identical to Median-B/NB</td>
              <td rowspan="1" colspan="1">For each experimental replicate, sgRNA counts are normalized to final time point counts across single, control and dual targeting sgRNAs.</td>
              <td rowspan="1" colspan="1">identical to Median-B/NB</td>
              <td rowspan="1" colspan="1">identical to Median-B, first calculated on sgRNA level then gene level through median</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">sgRNA-derived SL without background control normalization (sgRNA-NB)</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">identical to Median-NB, first calculated on sgRNA level then gene level through median</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
    </sec>
    <sec id="SEC2-3">
      <title>Synthetic lethality knowledge base (SLKB)</title>
      <p><bold>Data:</bold> The synthetic lethality knowledge base (SLKB) built on the 11 SL CDKO experiments (Table <xref rid="tbl1" ref-type="table">1</xref>) stores the sgRNA counts, library sequences and original gene-pair SL scores (Figure <xref rid="F2" ref-type="fig">2A</xref>) of the original CDKO studies, and it implements five scoring algorithms: Horlbeck score (<xref rid="B14" ref-type="bibr">14</xref>), MAGeCK score, GEMINI score (<xref rid="B12" ref-type="bibr">12</xref>), median-background/no background (Median-B/NB) scores, and sgRNA derived-background/no background (sgRNA-B/NB) scores (Supplementary File). Each approach has its own preprocessing steps, is applied to the sgRNA data of every CDKO experiment in the database (Figure <xref rid="F2" ref-type="fig">2B</xref>) and calculates SL scores based on the information in each CDKO library, e.g. guides, targets and/or sequences. For the first time, we assess the impact of SL scoring methods on the identification of synthetic lethality gene pairs.</p>
      <fig position="float" id="F2">
        <label>Figure 2.</label>
        <caption>
          <p>Overview of synthetic lethality knowledge base (SLKB). <bold>(A)</bold> Outline of data curation. <bold>(B)</bold> Outline of analysis pipeline.</p>
        </caption>
        <graphic xlink:href="gkad806fig2" position="float"/>
      </fig>
      <p><bold>Back-end database:</bold> Figure <xref rid="F3" ref-type="fig">3</xref> shows the relational MySQL database housed in the SLKB that contains both the original SL scores and the new scores from seven scoring approaches. The database is accessed by the front-end functions of the SLKB. The available tables can be downloaded both as an SQL (structured query language) dump file and as a CSV (comma separated values) file.</p>
      <fig position="float" id="F3">
        <label>Figure 3.</label>
        <caption>
          <p>Schema of synthetic lethality knowledge base (SLKB). <bold>(A)</bold> Back-end database. <bold>(B)</bold> Joined table of SL score calculation methods.</p>
        </caption>
        <graphic xlink:href="gkad806fig3" position="float"/>
      </fig>
      <p><bold>SLKB front-end functions</bold>: The SLKB is hosted as an R Shiny web application running R v.4.2.1 and Shiny v.1.7.3. The knowledge base includes an overview of the SLKB and the latest updates, a browsing table for SL-pair data for the CDKO studies, a choice of network visualization format, a page for downloading processed and raw data files, a references page and the option of a Venn-diagram comparison of SL pairs across the SLKB scoring approaches. Additionally, the data browsers include a brief description for each study and cell line to aid the selection of SL pairs. The SLKB pipeline, used for knowledge base creation, CDKO data insertion and score calculation, is available as a Python package and can be accessed through SLKB or GitHub.</p>
      <p><bold>Browsing SLKB CDKO experiments:</bold> Users can browse each study in either tabular or network format (Figure <xref rid="F4" ref-type="fig">4</xref>). Both formats provide a study panel to the left that offers users brief descriptions of the CDKO studies and the choice of which studies and cell lines to browse. They can also browse all SL scores available in the SLKB or all cell lines available within a study. A toggle switch on the panel for SL relationships filters the browsed data to significant SL pairs identified by each study. The tabular format allows users to navigate through a table to browse CDKO SL scores and their statistical scores for significance. Users can sort and filter the SL interactions by genes or scores within the table (Figure <xref rid="F4" ref-type="fig">4A</xref>). The network format enables users to search for genes and presents all interactions within the chosen studies and cell lines. Nodes of the networks are colored based on the number of interactions each query gene shares across the query SL network (Figure <xref rid="F4" ref-type="fig">4B</xref>). The tabular format is available under ‘Browse SL Score’ and the network format is available under ‘Browse SL Network’ within the SLKB.</p>
      <fig position="float" id="F4">
        <label>Figure 4.</label>
        <caption>
          <p>Synthetic lethality knowledge base (SLKB) website functionalities (original data). <bold>(A)</bold> Tabular data browsing. SL pairs from Horlbeck <italic toggle="yes">et al.</italic> are illustrated (<xref rid="B14" ref-type="bibr">14</xref>). <bold>(B)</bold> SL network and pair visualization. SL network of <italic toggle="yes">ARL2</italic>, <italic toggle="yes">FAM50A</italic>, <italic toggle="yes">POLD1</italic>, <italic toggle="yes">WDR61</italic> from Jurkat cell line in Horlbeck <italic toggle="yes">et al.</italic> is illustrated.</p>
        </caption>
        <graphic xlink:href="gkad806fig4" position="float"/>
      </fig>
      <p><bold>Browsing SLKB scoring approaches:</bold> Users can browse SLKB-calculated scores by tabular format or interactive Venn diagram presentation (Figure <xref rid="F5" ref-type="fig">5</xref>). Similar to the options for browsing CDKO original scores, each scoring approach includes a study panel that allows users to navigate the desired data sets and a toggle button that permits browsing of significantly SL pairs. The tabular browsing presents all scoring approaches and their statistical scores. As with the options for managing the original scores, users can sort and filter the SL interactions based on their input. Interactive Venn diagrams, on the other hand, permit users to navigate all computed SL interactions and extract overlapping interactions. By default, the top 10% of selected pairs from each approach are visualized along with their respective cutoff scores. Normally, Median-B and sgRNA-B scores are used in the Venn diagram, but Median-NB and sgRNA-NB scores are used if a study has no available dual-targeting controls. The tabular format is available under ‘Query KB’, and Venn diagrams are available under ‘Compare SL Approaches’ within the SLKB.</p>
      <fig position="float" id="F5">
        <label>Figure 5.</label>
        <caption>
          <p>Synthetic lethality knowledge base (SLKB) website functionalities (calculated data). <bold>(A)</bold> Knowledge-base query allows user access to all data within the KB. <bold>(B)</bold> Venn diagrams of SL scoring methods allow users to specify score thresholds for choosing gene pairs.</p>
        </caption>
        <graphic xlink:href="gkad806fig5" position="float"/>
      </fig>
    </sec>
  </sec>
  <sec sec-type="results" id="SEC3">
    <title>Results and discussion</title>
    <sec id="SEC3-1">
      <title>SLKB content</title>
      <p>Table <xref rid="tbl3" ref-type="table">3</xref> summarizes the SLKB content. The knowledge base currently stores the data of 11 CDKO SL studies, which includes counts for 10 of the 11 that were registered to the database. The database houses 3,578,017 sgRNA pair counts and 45,430 sgRNA sequences. Variation of sgRNA libraries across different studies produces varied data. For example, targeting could involve either the SL potential of a specific gene, such as the paralog gene pairs reported by Parrish's team (<xref rid="B15" ref-type="bibr">15</xref>) or pairwise interactions for a set of genes, as reflected on the gene map of Horlbeck and colleagues (<xref rid="B14" ref-type="bibr">14</xref>). The original reported SL scores contained scores for 6,127 unique genes among 280,483 gene pairs, of which 16,059 were found to be synthetic lethal. The 10 CDKO studies with counts yielded 261,958 gene pairs for 6,124 unique genes, and each study and cell line was equipped with five different scoring approaches. We extracted the top 10% of pairs predicted as synthetic lethal from the five main methods and identified a pair as SL only if at least three of the methods agreed on the pair's synthetic lethality, namely the majority vote. The comparison was made between Median-B, sgRNA-derived-B, GEMINI score, Horlbeck score and MAGeCK score. If a study had no dual targeting controls (<xref rid="B16" ref-type="bibr">16</xref>,<xref rid="B17" ref-type="bibr">17</xref>), Median-NB and sgRNA-derived-NB scores were used. Through this agreement, the SLKB contains 13,173 SL interactions and 248,785 non-SL interactions. Majority vote interactions can be downloaded from the SLKB website.</p>
      <table-wrap position="float" id="tbl3">
        <label>Table 3.</label>
        <caption>
          <p>Contents of synthetic lethality knowledge base (SLKB)</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th rowspan="1" colspan="1">Category</th>
              <th rowspan="1" colspan="1">Stored content</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td colspan="2" align="left" rowspan="1">
                <bold>SLKB study reported content</bold>
              </td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">No. of SL CDKO studies</td>
              <td rowspan="1" colspan="1">11 (currently counts available for 10)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">No. of sgRNA guides + sequences</td>
              <td rowspan="1" colspan="1">45,430 sgRNAs (1802 controls)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">No. of sgRNA pair counts</td>
              <td rowspan="1" colspan="1">3,578,017 sgRNA pairs</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">No. of unique genes and gene pairs</td>
              <td rowspan="1" colspan="1">6,127 genes/280,483 gene pairs (148,040 unique)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">No. of SL pairs (originally reported)</td>
              <td rowspan="1" colspan="1">16,059 gene pairs</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">No. of non-SL pairs (originally reported)</td>
              <td rowspan="1" colspan="1">264,424 gene pairs</td>
            </tr>
            <tr>
              <td colspan="2" align="left" rowspan="1">
                <bold>SLKB processed content</bold>
              </td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">No. of unique genes and gene pairs (calculated scores)</td>
              <td rowspan="1" colspan="1">6,124 genes/261,958 gene pairs (127,688 unique)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">No.# of SL pairs (majority vote)</td>
              <td rowspan="1" colspan="1">13,173 gene pairs</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">No. of non-SL pairs (majority vote)</td>
              <td rowspan="1" colspan="1">248,785 gene pairs</td>
            </tr>
            <tr>
              <td colspan="2" align="left" rowspan="1">
                <bold>SL connectivity hubs</bold>
              </td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">No. of SL hub clusters (containing at least 3 genes through SL interactions)</td>
              <td rowspan="1" colspan="1">865</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">No. of giant SL hub clusters (containing &gt;10 genes through SL interactions)</td>
              <td rowspan="1" colspan="1">67</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">No. of mega <bold>SL</bold><bold>hub</bold><bold>clusters (containing &gt;20 genes through SL interactions)</bold></td>
              <td rowspan="1" colspan="1">10</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
    </sec>
    <sec id="SEC3-2">
      <title>SL scoring approaches are highly varied</title>
      <p>The SLKB uses Venn diagrams to compare scoring approaches and run the scoring analyses on every study's cell lines and checking for overlapping pairs reflected substantial variation among scoring approaches. By default, the top 10% of predicted pairs for each algorithm were categorized as synthetic lethal. On average, only 1.21% of the pairs intersected across the five main scoring approaches, and each approach had its own exclusive gene pairs. While exclusive pairs for individual methods were statistically not significant, overlapped pairs among different methods were highly significant (Table <xref rid="tbl4" ref-type="table">4</xref>, binomial distribution test on data of Figure <xref rid="F5" ref-type="fig">5</xref>). Additionally, analysis of pairwise overlapping revealed overlapping rates of Median-B/NB score (50.6%), followed by MAGeCK score (49.31%), sgRNA-derived B/NB score (42.68%), Horlbeck score (27.94%) and GEMINI score (20.94%). Top overlapping scores used log fold change (LFC) as the basis for their score calculation, thus they yielded high overlaps.</p>
      <table-wrap position="float" id="tbl4">
        <label>Table 4.</label>
        <caption>
          <p>Analysis of overlapping synthetic lethal pairs across methods</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th rowspan="1" colspan="1">Comparisons</th>
              <th rowspan="1" colspan="1">Observed overlapping frequency</th>
              <th rowspan="1" colspan="1">Observed overlapping frequency relative frequency among all SL gene pairs <bold>(75,028) (%)</bold></th>
              <th rowspan="1" colspan="1">Observed overlapping relative frequency among all top 10% SL gene pairs <bold>(23,342) (%)</bold></th>
              <th rowspan="1" colspan="1">Expected overlapping frequency</th>
              <th rowspan="1" colspan="1">Enrichment ratio (observed overlapping frequency/ expected overlapping frequency)</th>
              <th rowspan="1" colspan="1"><italic toggle="yes">P</italic>-value</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">All five methods</td>
              <td rowspan="1" colspan="1">192</td>
              <td rowspan="1" colspan="1">0.26</td>
              <td rowspan="1" colspan="1">0.82</td>
              <td rowspan="1" colspan="1">0.75</td>
              <td rowspan="1" colspan="1">256</td>
              <td rowspan="1" colspan="1">1.9e-93</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">GEMINI score vs MAGeCK score</td>
              <td rowspan="1" colspan="1">
                <bold>2,937</bold>
              </td>
              <td rowspan="1" colspan="1">3.92</td>
              <td rowspan="1" colspan="1">12.58</td>
              <td rowspan="1" colspan="1">750</td>
              <td rowspan="1" colspan="1">3.916</td>
              <td rowspan="1" colspan="1">1.9e-93</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">GEMINI score vs Horlbeck score</td>
              <td rowspan="1" colspan="1">
                <bold>1,755</bold>
              </td>
              <td rowspan="1" colspan="1">2.34</td>
              <td rowspan="1" colspan="1">7.52</td>
              <td rowspan="1" colspan="1">750</td>
              <td rowspan="1" colspan="1">2.34</td>
              <td rowspan="1" colspan="1">1.9e-93</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">GEMINI score vs Median-B/NB score</td>
              <td rowspan="1" colspan="1">647</td>
              <td rowspan="1" colspan="1">0.86</td>
              <td rowspan="1" colspan="1">2.77</td>
              <td rowspan="1" colspan="1">750</td>
              <td rowspan="1" colspan="1">0.86</td>
              <td rowspan="1" colspan="1">1</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">GEMINI score vs sgRNA-derived B/NB score</td>
              <td rowspan="1" colspan="1">553</td>
              <td rowspan="1" colspan="1">0.74</td>
              <td rowspan="1" colspan="1">2.37</td>
              <td rowspan="1" colspan="1">750</td>
              <td rowspan="1" colspan="1">0.74</td>
              <td rowspan="1" colspan="1">1</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">MAGeCK score vs Horlbeck score</td>
              <td rowspan="1" colspan="1">
                <bold>1,905</bold>
              </td>
              <td rowspan="1" colspan="1">2.54</td>
              <td rowspan="1" colspan="1">8.16</td>
              <td rowspan="1" colspan="1">750</td>
              <td rowspan="1" colspan="1">2.54</td>
              <td rowspan="1" colspan="1">1.9e-93</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">MAGeCK score vs Median-B/ NB score</td>
              <td rowspan="1" colspan="1">
                <bold>2,080</bold>
              </td>
              <td rowspan="1" colspan="1">2.77</td>
              <td rowspan="1" colspan="1">8.91</td>
              <td rowspan="1" colspan="1">750</td>
              <td rowspan="1" colspan="1">2.77</td>
              <td rowspan="1" colspan="1">1.9e-93</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">MAGeCK score vs sgRNA-derived B/NB score</td>
              <td rowspan="1" colspan="1">
                <bold>2,097</bold>
              </td>
              <td rowspan="1" colspan="1">2.80</td>
              <td rowspan="1" colspan="1">8.98</td>
              <td rowspan="1" colspan="1">750</td>
              <td rowspan="1" colspan="1">2.80</td>
              <td rowspan="1" colspan="1">1.9e-93</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Horlbeck score vs Median-B/NB score</td>
              <td rowspan="1" colspan="1">
                <bold>1,648</bold>
              </td>
              <td rowspan="1" colspan="1">2.20</td>
              <td rowspan="1" colspan="1">7.06</td>
              <td rowspan="1" colspan="1">750</td>
              <td rowspan="1" colspan="1">2.20</td>
              <td rowspan="1" colspan="1">1.9e-93</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Horlbeck score vs sgRNA-derived B/NB score</td>
              <td rowspan="1" colspan="1">
                <bold>2,137</bold>
              </td>
              <td rowspan="1" colspan="1">2.85</td>
              <td rowspan="1" colspan="1">9.16</td>
              <td rowspan="1" colspan="1">750</td>
              <td rowspan="1" colspan="1">2.85</td>
              <td rowspan="1" colspan="1">1.9e-93</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Median-B/NB score vs sgRNA-derived B/NB score</td>
              <td rowspan="1" colspan="1">
                <bold>3,949</bold>
              </td>
              <td rowspan="1" colspan="1">5.26</td>
              <td rowspan="1" colspan="1">16.92</td>
              <td rowspan="1" colspan="1">750</td>
              <td rowspan="1" colspan="1">5.27</td>
              <td rowspan="1" colspan="1">1.9e-93</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">GEMINI score only</td>
              <td rowspan="1" colspan="1">
                <bold>3,532</bold>
              </td>
              <td rowspan="1" colspan="1">4.71</td>
              <td rowspan="1" colspan="1">15.13</td>
              <td rowspan="1" colspan="1">
                <bold>4,921</bold>
              </td>
              <td rowspan="1" colspan="1">0.73</td>
              <td rowspan="1" colspan="1">1</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">MAGeCK score only</td>
              <td rowspan="1" colspan="1">
                <bold>1,995</bold>
              </td>
              <td rowspan="1" colspan="1">2.66</td>
              <td rowspan="1" colspan="1">8.55</td>
              <td rowspan="1" colspan="1">
                <bold>4,921</bold>
              </td>
              <td rowspan="1" colspan="1">0.41</td>
              <td rowspan="1" colspan="1">1</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Horlbeck score only</td>
              <td rowspan="1" colspan="1">
                <bold>3,308</bold>
              </td>
              <td rowspan="1" colspan="1">4.41</td>
              <td rowspan="1" colspan="1">14.17</td>
              <td rowspan="1" colspan="1">
                <bold>4,921</bold>
              </td>
              <td rowspan="1" colspan="1">0.67</td>
              <td rowspan="1" colspan="1">1</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Median-B/NB score only</td>
              <td rowspan="1" colspan="1">
                <bold>2,441</bold>
              </td>
              <td rowspan="1" colspan="1">3.25</td>
              <td rowspan="1" colspan="1">10.46</td>
              <td rowspan="1" colspan="1">
                <bold>4,921</bold>
              </td>
              <td rowspan="1" colspan="1">0.50</td>
              <td rowspan="1" colspan="1">1</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">sgRNA-derived B/NB score only</td>
              <td rowspan="1" colspan="1">
                <bold>2,100</bold>
              </td>
              <td rowspan="1" colspan="1">2.80</td>
              <td rowspan="1" colspan="1">9.00</td>
              <td rowspan="1" colspan="1">
                <bold>4,921</bold>
              </td>
              <td rowspan="1" colspan="1">0.43</td>
              <td rowspan="1" colspan="1">1</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="T4TFN1">
            <p>Note: The null hypothesis is that all five SL calculation methods are independent tests, and the overlapping among their top 10% SL gene pairs are random. An alternative hypothesis is that several SL calculation methods have more enriched overlapping SL gene pairs than their overlapping gene pairs randomly. A binominal distribution is used to calculate the p-value for this enrichment analysis for overlapping gene pairs, <italic toggle="yes">P</italic> value = Prob (<italic toggle="yes">n</italic><inline-formula><tex-math id="M0006" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$ \ge$\end{document}</tex-math></inline-formula> observed overlapping gene pair frequency | <italic toggle="yes">p</italic> = expected gene pair frequency/<italic toggle="yes">N</italic>, <italic toggle="yes">N</italic><bold>= 75,028)</bold>.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
    </sec>
    <sec id="SEC3-3">
      <title>SL connectivity hub</title>
      <p>Although synthetic lethal pairs are very sparse, we identified a pattern in SL interactions among genes (Figure <xref rid="F6" ref-type="fig">6A</xref>): SL hub clusters (i.e. SL interactions across (&gt;2 genes) and SL hub genes (i.e. genes with numerous SL interactions). The SLKB contains 865 SL hub clusters, 67 hub clusters with &gt;10 genes and 10 hub clusters with &gt;20 genes (Table <xref rid="tbl3" ref-type="table">3</xref>) based on the study-reported SL pairs. We believe that SL genes are more likely to be connected with each other than with non-SL genes, but we also observed the separation of many large SL hubs among different SL studies, with sparse SL connections between studies largely attributable to the limited overlap of SL gene sets among SL studies. Owing to lack of experiment validations for top ranked SL gene pairs screened from existing CDKO experiments, currently there is no positive control for the SL and SL connectivity hub.</p>
      <fig position="float" id="F6">
        <label>Figure 6.</label>
        <caption>
          <p>Synthetic lethality (SL) connectivity hub. <bold>(A)</bold> All available SL networks, separated by study. <bold>(B)</bold> Jurkat and K562 SL networks and hubs (Horlbeck <italic toggle="yes">et al.</italic> 2018) (<xref rid="B14" ref-type="bibr">14</xref>).</p>
        </caption>
        <graphic xlink:href="gkad806fig6" position="float"/>
      </fig>
      <p>We also looked into similarities of SL patterns between cell lines when the same gene set was studied (Figure <xref rid="F6" ref-type="fig">6B</xref>). For instance, Horlbeck's study targeted Jurkat and K562 cell lines, and their SL studies shared 378 genes for a total of 458 genes (<xref rid="B14" ref-type="bibr">14</xref>). Despite a reported 374 SL gene pairs in Jurkat cells and 1,523 SL gene pairs in K562 cells, only 82 SL gene pairs overlapped between the two. However, the two cell lines share five of the top 15 hub genes, <italic toggle="yes">ARL2</italic>, <italic toggle="yes">LEO1</italic>, <italic toggle="yes">HUS1</italic>, <italic toggle="yes">MED23</italic> and <italic toggle="yes">WDR61</italic>, suggesting the greater reliability of hub genes as SL network features in understanding the molecular mechanism. Within SLKB, SL gene pairs can be queried against different studies, cell lines and both to assess their conservation across different contexts (Figure <xref rid="F7" ref-type="fig">7</xref>).</p>
      <fig position="float" id="F7">
        <label>Figure 7.</label>
        <caption>
          <p>Sample SL gene pair query under ‘Query KB’ webpage. EZH2, GART, MAPK1, MAPK3 and PIK3C3 genes’ SL connectivity is visualized across <bold>(A)</bold> cell lines and <bold>(B)</bold> studies. Different colors indicate interactions within different cell line and study contexts.</p>
        </caption>
        <graphic xlink:href="gkad806fig7" position="float"/>
      </fig>
    </sec>
  </sec>
  <sec sec-type="conclusions" id="SEC4">
    <title>Conclusion</title>
    <p>Following the latest trends in CRISPR–Cas9 technologies and their performance in the identification of synthetic lethal genes, CDKO studies pave the way for future SL experiments. The SLKB we have developed focuses on the curation of SL data from CDKO studies and presents both original study scores and new SL scores from seven new scoring approaches. To the best of our knowledge, our SLKB is the first SL database that houses all CDKO SL pairs and includes both reported original scores and scores from multiple SL calculation methods. We recognize that different assumptions in methodology generate highly diverse SL scoring approaches, but we observed statistically significant overlap of the top 10% scores across all five approaches. Their overlapped SL gene pairs are more trustworthy than SL gene pairs belonging to an individual SL score calculation method. Median-B/NB score showed the highest overlap (50.6%) with the other approaches. The SLKB offers interactive Venn diagrams that allow users to choose SL pairs that overlap across different scores, and the developed SLKB analysis pipeline is equipped with preprocessing and scoring approaches that permit users to analyze their own CDKO studies. We observed SL hubs and genes that retained their connectivity in different contexts, and users can choose their targets of interest among the available cell lines through these hubs. In the future, the SLKB will continue to curate CDKO SL studies and implement additional scoring approaches where available.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="sup1" position="float" content-type="local-data">
      <label>gkad806_Supplemental_Files</label>
      <media xlink:href="gkad806_supplemental_files.zip">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack id="ACK1">
    <title>Acknowledgements</title>
    <p>The authors thank the research computing services at Ohio Supercomputer Center (OSC) for providing computational resources throughout the study.</p>
  </ack>
  <sec sec-type="data-availability" id="SEC5">
    <title>Data availability</title>
    <p>The SLKB knowledge base and analysis pipelines are both available in the public domain. The SLKB can be freely accessed at <ext-link xlink:href="https://slkb.osubmi.org" ext-link-type="uri">https://slkb.osubmi.org</ext-link>. SLKB's data and pipeline are stored in <ext-link xlink:href="https://doi.org/10.6084/m9.figshare.22902839" ext-link-type="uri">https://doi.org/10.6084/m9.figshare.22902839</ext-link> and <ext-link xlink:href="https://doi.org/10.5281/zenodo.8274172" ext-link-type="uri">https://doi.org/10.5281/zenodo.8274172</ext-link> respectively, under GNU General Public License v.3.0. The documentation can be accessed from <ext-link xlink:href="https://slkb.docs.osubmi.org/" ext-link-type="uri">https://slkb.docs.osubmi.org/</ext-link>.</p>
  </sec>
  <sec id="SEC6">
    <title>Supplementary data</title>
    <p><ext-link xlink:href="https://academic.oup.com/nar/article-lookup/doi/10.1093/nar/gkad806#supplementary-data" ext-link-type="uri">Supplementary Data</ext-link> are available at NAR Online.</p>
  </sec>
  <sec id="SEC7">
    <title>Funding</title>
    <p>Internal funding from The Ohio State University.</p>
    <p><italic toggle="yes">Conflict of interest statement</italic>. None declared.</p>
  </sec>
  <ref-list id="REF1">
    <title>References</title>
    <ref id="B1">
      <label>1.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kaelin</surname><given-names>W.G.</given-names><suffix>Jr</suffix></string-name></person-group><article-title>The concept of synthetic lethality in the context of anticancer therapy</article-title>. <source>Nat. Rev. Cancer</source>. <year>2005</year>; <volume>5</volume>:<fpage>689</fpage>–<lpage>698</lpage>.<pub-id pub-id-type="pmid">16110319</pub-id></mixed-citation>
    </ref>
    <ref id="B2">
      <label>2.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hartwell</surname><given-names>L.H.</given-names></string-name>, <string-name><surname>Szankasi</surname><given-names>P.</given-names></string-name>, <string-name><surname>Roberts</surname><given-names>C.J.</given-names></string-name>, <string-name><surname>Murray</surname><given-names>A.W.</given-names></string-name>, <string-name><surname>Friend</surname><given-names>S.H.</given-names></string-name></person-group><article-title>Integrating genetic approaches into the discovery of anticancer drugs</article-title>. <source>Science</source>. <year>1997</year>; <volume>278</volume>:<fpage>1064</fpage>–<lpage>1068</lpage>.<pub-id pub-id-type="pmid">9353181</pub-id></mixed-citation>
    </ref>
    <ref id="B3">
      <label>3.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cortesi</surname><given-names>L.</given-names></string-name>, <string-name><surname>Rugo</surname><given-names>H.S.</given-names></string-name>, <string-name><surname>Jackisch</surname><given-names>C.</given-names></string-name></person-group><article-title>An overview of PARP inhibitors for the treatment of breast cancer</article-title>. <source>Target Oncol</source>. <year>2021</year>; <volume>16</volume>:<fpage>255</fpage>–<lpage>282</lpage>.<pub-id pub-id-type="pmid">33710534</pub-id></mixed-citation>
    </ref>
    <ref id="B4">
      <label>4.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>J.</given-names></string-name>, <string-name><surname>Wu</surname><given-names>M.</given-names></string-name>, <string-name><surname>Huang</surname><given-names>X.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>L.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>S.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>H.</given-names></string-name>, <string-name><surname>Zheng</surname><given-names>J.</given-names></string-name></person-group><article-title>SynLethDB 2.0: a web-based knowledge graph database on synthetic lethality for novel anticancer drug discovery</article-title>. <source>Database (Oxford)</source>. <year>2022</year>; <volume>2022</volume>:<fpage>baac030</fpage>.<pub-id pub-id-type="pmid">35562840</pub-id></mixed-citation>
    </ref>
    <ref id="B5">
      <label>5.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bragin</surname><given-names>E.</given-names></string-name>, <string-name><surname>Chatzimichali</surname><given-names>E.A.</given-names></string-name>, <string-name><surname>Wright</surname><given-names>C.F.</given-names></string-name>, <string-name><surname>Hurles</surname><given-names>M.E.</given-names></string-name>, <string-name><surname>Firth</surname><given-names>H.V.</given-names></string-name>, <string-name><surname>Bevan</surname><given-names>A.P.</given-names></string-name>, <string-name><surname>Swaminathan</surname><given-names>G.J.</given-names></string-name></person-group><article-title>DECIPHER: database for the interpretation of phenotype-linked plausibly pathogenic sequence and copy-number variation</article-title>. <source>Nucleic Acids Res.</source><year>2014</year>; <volume>42</volume>:<fpage>D993</fpage>–<lpage>D1000</lpage>.<pub-id pub-id-type="pmid">24150940</pub-id></mixed-citation>
    </ref>
    <ref id="B6">
      <label>6.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname><given-names>X.J.</given-names></string-name>, <string-name><surname>Mishra</surname><given-names>S.K.</given-names></string-name>, <string-name><surname>Wu</surname><given-names>M.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>F.</given-names></string-name>, <string-name><surname>Zheng</surname><given-names>J.</given-names></string-name></person-group><article-title>Syn-lethality: an integrative knowledge base of synthetic lethality towards discovery of selective anticancer therapies</article-title>. <source>Biomed. Res. Int.</source><year>2014</year>; <volume>2014</volume>:<fpage>196034</fpage>.<pub-id pub-id-type="pmid">24864230</pub-id></mixed-citation>
    </ref>
    <ref id="B7">
      <label>7.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jerby-Arnon</surname><given-names>L.</given-names></string-name>, <string-name><surname>Pfetzer</surname><given-names>N.</given-names></string-name>, <string-name><surname>Waldman</surname><given-names>Y.Y.</given-names></string-name>, <string-name><surname>McGarry</surname><given-names>L.</given-names></string-name>, <string-name><surname>James</surname><given-names>D.</given-names></string-name>, <string-name><surname>Shanks</surname><given-names>E.</given-names></string-name>, <string-name><surname>Seashore-Ludlow</surname><given-names>B.</given-names></string-name>, <string-name><surname>Weinstock</surname><given-names>A.</given-names></string-name>, <string-name><surname>Geiger</surname><given-names>T.</given-names></string-name>, <string-name><surname>Clemons</surname><given-names>P.A.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Predicting cancer-specific vulnerability via data-driven detection of synthetic lethality</article-title>. <source>Cell</source>. <year>2014</year>; <volume>158</volume>:<fpage>1199</fpage>–<lpage>1209</lpage>.<pub-id pub-id-type="pmid">25171417</pub-id></mixed-citation>
    </ref>
    <ref id="B8">
      <label>8.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bartz</surname><given-names>S.R.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Burchard</surname><given-names>J.</given-names></string-name>, <string-name><surname>Imakura</surname><given-names>M.</given-names></string-name>, <string-name><surname>Martin</surname><given-names>M.</given-names></string-name>, <string-name><surname>Palmieri</surname><given-names>A.</given-names></string-name>, <string-name><surname>Needham</surname><given-names>R.</given-names></string-name>, <string-name><surname>Guo</surname><given-names>J.</given-names></string-name>, <string-name><surname>Gordon</surname><given-names>M.</given-names></string-name>, <string-name><surname>Chung</surname><given-names>N.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions</article-title>. <source>Mol. Cell. Biol.</source><year>2006</year>; <volume>26</volume>:<fpage>9377</fpage>–<lpage>9386</lpage>.<pub-id pub-id-type="pmid">17000754</pub-id></mixed-citation>
    </ref>
    <ref id="B9">
      <label>9.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>X.</given-names></string-name>, <string-name><surname>Fu</surname><given-names>A.Q.</given-names></string-name>, <string-name><surname>McNerney</surname><given-names>M.E.</given-names></string-name>, <string-name><surname>White</surname><given-names>K.P.</given-names></string-name></person-group><article-title>Widespread genetic epistasis among cancer genes</article-title>. <source>Nat. Commun.</source><year>2014</year>; <volume>5</volume>:<fpage>4828</fpage>.<pub-id pub-id-type="pmid">25407795</pub-id></mixed-citation>
    </ref>
    <ref id="B10">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pathak</surname><given-names>H.B.</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Sethi</surname><given-names>G.</given-names></string-name>, <string-name><surname>Hirst</surname><given-names>J.</given-names></string-name>, <string-name><surname>Schilder</surname><given-names>R.J.</given-names></string-name>, <string-name><surname>Golemis</surname><given-names>E.A.</given-names></string-name>, <string-name><surname>Godwin</surname><given-names>A.K.</given-names></string-name></person-group><article-title>A synthetic lethality screen using a focused siRNA library to identify sensitizers to dasatinib therapy for the treatment of epithelial ovarian cancer</article-title>. <source>PLoS ONE</source>. <year>2015</year>; <volume>10</volume>:<fpage>e0144126</fpage>.<pub-id pub-id-type="pmid">26637171</pub-id></mixed-citation>
    </ref>
    <ref id="B11">
      <label>11.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tang</surname><given-names>S.</given-names></string-name>, <string-name><surname>Wu</surname><given-names>X.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>J.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>X.</given-names></string-name>, <string-name><surname>Shao</surname><given-names>S.</given-names></string-name>, <string-name><surname>Gokbag</surname><given-names>B.</given-names></string-name>, <string-name><surname>Fan</surname><given-names>K.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>X.</given-names></string-name>, <string-name><surname>Li</surname><given-names>F.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Generation of dual-gRNA library for combinatorial CRISPR screening of synthetic lethal gene pairs</article-title>. <source>STAR Protoc.</source><year>2022</year>; <volume>3</volume>:<fpage>101556</fpage>.<pub-id pub-id-type="pmid">36060092</pub-id></mixed-citation>
    </ref>
    <ref id="B12">
      <label>12.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zamanighomi</surname><given-names>M.</given-names></string-name>, <string-name><surname>Jain</surname><given-names>S.S.</given-names></string-name>, <string-name><surname>Ito</surname><given-names>T.</given-names></string-name>, <string-name><surname>Pal</surname><given-names>D.</given-names></string-name>, <string-name><surname>Daley</surname><given-names>T.P.</given-names></string-name>, <string-name><surname>Sellers</surname><given-names>W.R.</given-names></string-name></person-group><article-title>GEMINI: a variational Bayesian approach to identify genetic interactions from combinatorial CRISPR screens</article-title>. <source>Genome Biol.</source><year>2019</year>; <volume>20</volume>:<fpage>137</fpage>.<pub-id pub-id-type="pmid">31300006</pub-id></mixed-citation>
    </ref>
    <ref id="B13">
      <label>13.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname><given-names>W.</given-names></string-name>, <string-name><surname>Xu</surname><given-names>H.</given-names></string-name>, <string-name><surname>Xiao</surname><given-names>T.</given-names></string-name>, <string-name><surname>Cong</surname><given-names>L.</given-names></string-name>, <string-name><surname>Love</surname><given-names>M.I.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>F.</given-names></string-name>, <string-name><surname>Irizarry</surname><given-names>R.A.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>J.S.</given-names></string-name>, <string-name><surname>Brown</surname><given-names>M.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>X.S.</given-names></string-name></person-group><article-title>MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens</article-title>. <source>Genome Biol.</source><year>2014</year>; <volume>15</volume>:<fpage>554</fpage>.<pub-id pub-id-type="pmid">25476604</pub-id></mixed-citation>
    </ref>
    <ref id="B14">
      <label>14.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Horlbeck</surname><given-names>M.A.</given-names></string-name>, <string-name><surname>Xu</surname><given-names>A.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>M.</given-names></string-name>, <string-name><surname>Bennett</surname><given-names>N.K.</given-names></string-name>, <string-name><surname>Park</surname><given-names>C.Y.</given-names></string-name>, <string-name><surname>Bogdanoff</surname><given-names>D.</given-names></string-name>, <string-name><surname>Adamson</surname><given-names>B.</given-names></string-name>, <string-name><surname>Chow</surname><given-names>E.D.</given-names></string-name>, <string-name><surname>Kampmann</surname><given-names>M.</given-names></string-name>, <string-name><surname>Peterson</surname><given-names>T.R.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Mapping the genetic landscape of human cells</article-title>. <source>Cell</source>. <year>2018</year>; <volume>174</volume>:<fpage>953</fpage>–<lpage>967</lpage>.<pub-id pub-id-type="pmid">30033366</pub-id></mixed-citation>
    </ref>
    <ref id="B15">
      <label>15.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Parrish</surname><given-names>P.C.R.</given-names></string-name>, <string-name><surname>Thomas</surname><given-names>J.D.</given-names></string-name>, <string-name><surname>Gabel</surname><given-names>A.M.</given-names></string-name>, <string-name><surname>Kamlapurkar</surname><given-names>S.</given-names></string-name>, <string-name><surname>Bradley</surname><given-names>R.K.</given-names></string-name>, <string-name><surname>Berger</surname><given-names>A.H.</given-names></string-name></person-group><article-title>Discovery of synthetic lethal and tumor suppressor paralog pairs in the human genome</article-title>. <source>Cell Rep.</source><year>2021</year>; <volume>36</volume>:<fpage>109597</fpage>.<pub-id pub-id-type="pmid">34469736</pub-id></mixed-citation>
    </ref>
    <ref id="B16">
      <label>16.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhao</surname><given-names>D.</given-names></string-name>, <string-name><surname>Badur</surname><given-names>M.G.</given-names></string-name>, <string-name><surname>Luebeck</surname><given-names>J.</given-names></string-name>, <string-name><surname>Magaña</surname><given-names>J.H.</given-names></string-name>, <string-name><surname>Birmingham</surname><given-names>A.</given-names></string-name>, <string-name><surname>Sasik</surname><given-names>R.</given-names></string-name>, <string-name><surname>Ahn</surname><given-names>C.S.</given-names></string-name>, <string-name><surname>Ideker</surname><given-names>T.</given-names></string-name>, <string-name><surname>Metallo</surname><given-names>C.M.</given-names></string-name>, <string-name><surname>Mali</surname><given-names>P.</given-names></string-name></person-group><article-title>Combinatorial CRISPR-Cas9 metabolic screens reveal critical redox control points dependent on the KEAP1-NRF2 regulatory axis</article-title>. <source>Mol. Cell</source>. <year>2018</year>; <volume>69</volume>:<fpage>699</fpage>–<lpage>708</lpage>.<pub-id pub-id-type="pmid">29452643</pub-id></mixed-citation>
    </ref>
    <ref id="B17">
      <label>17.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ito</surname><given-names>T.</given-names></string-name>, <string-name><surname>Young</surname><given-names>M.J.</given-names></string-name>, <string-name><surname>Li</surname><given-names>R.</given-names></string-name>, <string-name><surname>Jain</surname><given-names>S.</given-names></string-name>, <string-name><surname>Wernitznig</surname><given-names>A.</given-names></string-name>, <string-name><surname>Krill-Burger</surname><given-names>J.M.</given-names></string-name>, <string-name><surname>Lemke</surname><given-names>C.T.</given-names></string-name>, <string-name><surname>Monducci</surname><given-names>D.</given-names></string-name>, <string-name><surname>Rodriguez</surname><given-names>D.J.</given-names></string-name>, <string-name><surname>Chang</surname><given-names>L.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Paralog knockout profiling identifies DUSP4 and DUSP6 as a digenic dependence in MAPK pathway-driven cancers</article-title>. <source>Nat. Genet.</source><year>2021</year>; <volume>53</volume>:<fpage>1664</fpage>–<lpage>1672</lpage>.<pub-id pub-id-type="pmid">34857952</pub-id></mixed-citation>
    </ref>
    <ref id="B18">
      <label>18.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wong</surname><given-names>A.S.L.</given-names></string-name>, <string-name><surname>Choi</surname><given-names>G.C.G.</given-names></string-name>, <string-name><surname>Cui</surname><given-names>C.H.</given-names></string-name>, <string-name><surname>Pregernig</surname><given-names>G.</given-names></string-name>, <string-name><surname>Milani</surname><given-names>P.</given-names></string-name>, <string-name><surname>Adam</surname><given-names>M.</given-names></string-name>, <string-name><surname>Perli</surname><given-names>S.D.</given-names></string-name>, <string-name><surname>Kazer</surname><given-names>S.W.</given-names></string-name>, <string-name><surname>Gaillard</surname><given-names>A.</given-names></string-name>, <string-name><surname>Hermann</surname><given-names>M.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Multiplexed barcoded CRISPR-Cas9 screening enabled by CombiGEM</article-title>. <source>Proc. Natl Acad. Sci. USA</source>. <year>2016</year>; <volume>113</volume>:<fpage>2544</fpage>–<lpage>2549</lpage>.<pub-id pub-id-type="pmid">26864203</pub-id></mixed-citation>
    </ref>
    <ref id="B19">
      <label>19.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Han</surname><given-names>K.</given-names></string-name>, <string-name><surname>Jeng</surname><given-names>E.E.</given-names></string-name>, <string-name><surname>Hess</surname><given-names>G.T.</given-names></string-name>, <string-name><surname>Morgens</surname><given-names>D.W.</given-names></string-name>, <string-name><surname>Li</surname><given-names>A.</given-names></string-name>, <string-name><surname>Bassik</surname><given-names>M.C.</given-names></string-name></person-group><article-title>Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions</article-title>. <source>Nat. Biotechnol.</source><year>2017</year>; <volume>35</volume>:<fpage>463</fpage>–<lpage>474</lpage>.<pub-id pub-id-type="pmid">28319085</pub-id></mixed-citation>
    </ref>
    <ref id="B20">
      <label>20.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shen</surname><given-names>J.P.</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>D.</given-names></string-name>, <string-name><surname>Sasik</surname><given-names>R.</given-names></string-name>, <string-name><surname>Luebeck</surname><given-names>J.</given-names></string-name>, <string-name><surname>Birmingham</surname><given-names>A.</given-names></string-name>, <string-name><surname>Bojorquez-Gomez</surname><given-names>A.</given-names></string-name>, <string-name><surname>Licon</surname><given-names>K.</given-names></string-name>, <string-name><surname>Klepper</surname><given-names>K.</given-names></string-name>, <string-name><surname>Pekin</surname><given-names>D.</given-names></string-name>, <string-name><surname>Beckett</surname><given-names>A.N.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Combinatorial CRISPR-Cas9 screens for de novo mapping of genetic interactions</article-title>. <source>Nat. Methods</source>. <year>2017</year>; <volume>14</volume>:<fpage>573</fpage>–<lpage>576</lpage>.<pub-id pub-id-type="pmid">28319113</pub-id></mixed-citation>
    </ref>
    <ref id="B21">
      <label>21.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Najm</surname><given-names>F.J.</given-names></string-name>, <string-name><surname>Strand</surname><given-names>C.</given-names></string-name>, <string-name><surname>Donovan</surname><given-names>K.F.</given-names></string-name>, <string-name><surname>Hegde</surname><given-names>M.</given-names></string-name>, <string-name><surname>Sanson</surname><given-names>K.R.</given-names></string-name>, <string-name><surname>Vaimberg</surname><given-names>E.W.</given-names></string-name>, <string-name><surname>Sullender</surname><given-names>M.E.</given-names></string-name>, <string-name><surname>Hartenian</surname><given-names>E.</given-names></string-name>, <string-name><surname>Kalani</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Fusi</surname><given-names>N.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Orthologous CRISPR-Cas9 enzymes for combinatorial genetic screens</article-title>. <source>Nat. Biotechnol.</source><year>2018</year>; <volume>36</volume>:<fpage>179</fpage>–<lpage>189</lpage>.<pub-id pub-id-type="pmid">29251726</pub-id></mixed-citation>
    </ref>
    <ref id="B22">
      <label>22.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Diehl</surname><given-names>V.</given-names></string-name>, <string-name><surname>Wegner</surname><given-names>M.</given-names></string-name>, <string-name><surname>Grumati</surname><given-names>P.</given-names></string-name>, <string-name><surname>Husnjak</surname><given-names>K.</given-names></string-name>, <string-name><surname>Schaubeck</surname><given-names>S.</given-names></string-name>, <string-name><surname>Gubas</surname><given-names>A.</given-names></string-name>, <string-name><surname>Shah</surname><given-names>V.J.</given-names></string-name>, <string-name><surname>Polat</surname><given-names>I.H.</given-names></string-name>, <string-name><surname>Langschied</surname><given-names>F.</given-names></string-name>, <string-name><surname>Prieto-Garcia</surname><given-names>C.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Minimized combinatorial CRISPR screens identify genetic interactions in autophagy</article-title>. <source>Nucleic Acids Res.</source><year>2021</year>; <volume>49</volume>:<fpage>5684</fpage>–<lpage>5704</lpage>.<pub-id pub-id-type="pmid">33956155</pub-id></mixed-citation>
    </ref>
    <ref id="B23">
      <label>23.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Thompson</surname><given-names>N.A.</given-names></string-name>, <string-name><surname>Ranzani</surname><given-names>M.</given-names></string-name>, <string-name><surname>van der Weyden</surname><given-names>L.</given-names></string-name>, <string-name><surname>Iyer</surname><given-names>V.</given-names></string-name>, <string-name><surname>Offord</surname><given-names>V.</given-names></string-name>, <string-name><surname>Droop</surname><given-names>A.</given-names></string-name>, <string-name><surname>Behan</surname><given-names>F.</given-names></string-name>, <string-name><surname>Gonçalves</surname><given-names>E.</given-names></string-name>, <string-name><surname>Speak</surname><given-names>A.</given-names></string-name>, <string-name><surname>Iorio</surname><given-names>F.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Combinatorial CRISPR screen identifies fitness effects of gene paralogues</article-title>. <source>Nat. Commun.</source><year>2021</year>; <volume>12</volume>:<fpage>1302</fpage>.<pub-id pub-id-type="pmid">33637726</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="iso-abbrev">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="publisher-id">nar</journal-id>
    <journal-title-group>
      <journal-title>Nucleic Acids Research</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">0305-1048</issn>
    <issn pub-type="epub">1362-4962</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10767912</article-id>
    <article-id pub-id-type="pmid">37889037</article-id>
    <article-id pub-id-type="doi">10.1093/nar/gkad806</article-id>
    <article-id pub-id-type="publisher-id">gkad806</article-id>
    <article-categories>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI00010</subject>
      </subj-group>
      <subj-group subj-group-type="heading">
        <subject>Database Issue</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>SLKB: synthetic lethality knowledge base</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9238-1650</contrib-id>
        <name>
          <surname>Gökbağ</surname>
          <given-names>Birkan</given-names>
        </name>
        <aff><institution>Department of Biomedical Informatics, College of Medicine, The Ohio State University</institution>, <addr-line>Columbus</addr-line>, <addr-line>OH</addr-line> 43210, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Tang</surname>
          <given-names>Shan</given-names>
        </name>
        <aff><institution>College of Pharmacy, The Ohio State University</institution>, <addr-line>Columbus</addr-line>, <addr-line>OH</addr-line> 43210, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0392-1177</contrib-id>
        <name>
          <surname>Fan</surname>
          <given-names>Kunjie</given-names>
        </name>
        <aff><institution>Department of Biomedical Informatics, College of Medicine, The Ohio State University</institution>, <addr-line>Columbus</addr-line>, <addr-line>OH</addr-line> 43210, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6336-5416</contrib-id>
        <name>
          <surname>Cheng</surname>
          <given-names>Lijun</given-names>
        </name>
        <aff><institution>Department of Biomedical Informatics, College of Medicine, The Ohio State University</institution>, <addr-line>Columbus</addr-line>, <addr-line>OH</addr-line> 43210, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Yu</surname>
          <given-names>Lianbo</given-names>
        </name>
        <aff><institution>Department of Biomedical Informatics, College of Medicine, The Ohio State University</institution>, <addr-line>Columbus</addr-line>, <addr-line>OH</addr-line> 43210, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zhao</surname>
          <given-names>Yue</given-names>
        </name>
        <aff><institution>Department of Computational Medicine and Bioinformatics, College of Medicine, University of Michigan</institution>, <addr-line>Ann Arbor</addr-line>, <addr-line>MI</addr-line> 48104, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0746-1809</contrib-id>
        <name>
          <surname>Li</surname>
          <given-names>Lang</given-names>
        </name>
        <!--lang.li@osumc.edu-->
        <aff><institution>Department of Biomedical Informatics, College of Medicine, The Ohio State University</institution>, <addr-line>Columbus</addr-line>, <addr-line>OH</addr-line> 43210, <country country="US">USA</country></aff>
        <xref rid="COR1" ref-type="corresp"/>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="COR1">To whom correspondence should be addressed. Email: <email>lang.li@osumc.edu</email></corresp>
    </author-notes>
    <pub-date pub-type="collection">
      <day>05</day>
      <month>1</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2023-10-27">
      <day>27</day>
      <month>10</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>27</day>
      <month>10</month>
      <year>2023</year>
    </pub-date>
    <volume>52</volume>
    <issue>D1</issue>
    <fpage>D1418</fpage>
    <lpage>D1428</lpage>
    <history>
      <date date-type="accepted">
        <day>27</day>
        <month>9</month>
        <year>2023</year>
      </date>
      <date date-type="rev-recd">
        <day>16</day>
        <month>8</month>
        <year>2023</year>
      </date>
      <date date-type="received">
        <day>04</day>
        <month>6</month>
        <year>2023</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2023. Published by Oxford University Press on behalf of Nucleic Acids Research.</copyright-statement>
      <copyright-year>2024</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact <email>journals.permissions@oup.com</email></license-p>
      </license>
    </permissions>
    <self-uri xlink:href="gkad806.pdf"/>
    <abstract>
      <title>Abstract</title>
      <p>Emerging CRISPR–Cas9 technology permits synthetic lethality (SL) screening of large number of gene pairs from gene combination double knockout (CDKO) experiments. However, the poor integration and annotation of CDKO SL data in current SL databases limit their utility, and diverse methods of calculating SL scores prohibit their comparison. To overcome these shortcomings, we have developed SL knowledge base (SLKB) that incorporates data of 11 CDKO experiments in 22 cell lines, 16,059 SL gene pairs and 264,424 non-SL gene pairs. Additionally, within SLKB, we have implemented five SL calculation methods: median score with and without background control normalization (Median-B/NB), sgRNA-derived score (sgRNA-B/NB), Horlbeck score, GEMINI score and MAGeCK score. The five scores have demonstrated a mere 1.21% overlap among their top 10% SL gene pairs, reflecting high diversity. Users can browse SL networks and assess the impact of scoring methods using Venn diagrams. The SL network generated from all data in SLKB shows a greater likelihood of SL gene pair connectivity with other SL gene pairs than non-SL pairs. Comparison of SL networks between two cell lines demonstrated greater likelihood to share SL hub genes than SL gene pairs. SLKB website and pipeline can be freely accessed at <ext-link xlink:href="https://slkb.osubmi.org" ext-link-type="uri">https://slkb.osubmi.org</ext-link> and <ext-link xlink:href="https://slkb.docs.osubmi.org/" ext-link-type="uri">https://slkb.docs.osubmi.org/</ext-link>, respectively.</p>
    </abstract>
    <abstract abstract-type="graphical">
      <title>Graphical Abstract</title>
      <p>
        <fig position="float" id="ga1">
          <label>Graphical Abstract</label>
          <graphic xlink:href="gkad806figgra1" position="float"/>
        </fig>
      </p>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Ohio State University</institution>
            <institution-id institution-id-type="DOI">10.13039/100006928</institution-id>
          </institution-wrap>
        </funding-source>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="11"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="SEC1">
    <title>Introduction</title>
    <p>Synthetic lethality (SL) describes an interaction between two genes in which impaired function of both genes results in cell death, but compromised function of only one of the pair does not (<xref rid="B1" ref-type="bibr">1</xref>). The identification of SL can be highly impactful in the discovery of new drug therapies for catastrophic illnesses, such as cancer, as exemplified by the observation of SL interaction between <italic toggle="yes">PARP1</italic> and <italic toggle="yes">BRAC1</italic> genes (<xref rid="B2" ref-type="bibr">2</xref>) that led to the development of <italic toggle="yes">PARP1</italic> inhibitors for the treatment of patients with breast or ovarian cancer with <italic toggle="yes">BRCA1</italic> mutations. Such <italic toggle="yes">PARP1</italic> inhibitors approved by the US Food and Drug Administration include olaparib (2018), niraparib (2020) and talazoparib (2022) (<xref rid="B3" ref-type="bibr">3</xref>).</p>
    <p>Substantial work has been done in creating databases for SL interactions, and the SynLethDB has been a major resource in the integration of SL data (<xref rid="B4" ref-type="bibr">4</xref>). Its recent 2.0 version houses data for 35,943 SL pairs and 2,899 non-SL pairs in human cells. The SL pairs are integrated from <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in silico</italic> sources. The <italic toggle="yes">in vitro</italic> study sources comprise investigations of genome-wide RNAi, drug inhibition, external databases, i.e. DECIPHER and Syn-lethality (<xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B6" ref-type="bibr">6</xref>), CRISPR inference and high- and low-throughput studies. <italic toggle="yes">In silico</italic> studies, e.g. DAISY (<xref rid="B7" ref-type="bibr">7</xref>), examine SL prediction. In the SynLethDB, each SL pair is scored using the probability function, which is weighted from various data sources. CRISPR-inferred pairs have a high weight (0.85), and high-throughput screening-inferred pairs are scored the lowest (0.50).</p>
    <p>However, SynLethDB has several knowledge gaps, including inadequate coverage of combination gene double knockout (CDKO) experiments, especially those based in CRISPR–Cas9 technology, as well as incomplete or inaccurate cell-line annotations, and the database fails to differentiate the methods of calculating SL scores from CDKO experimental data. Although the literature includes 11 published CDKO experiments (Table <xref rid="tbl1" ref-type="table">1</xref>), which collectively report 16,059 SL pairs and 264,424 non-SL pairs, SynLethDB includes only 7,312 SL pairs and 2,899 non-SL pairs from five CDKO data sets, and does not report the criteria for their selection. Furthermore, incomplete cell-line annotation includes SynLethDB’s annotation of only SL data for HeLa cells from a report by Bartz and associates (<xref rid="B8" ref-type="bibr">8</xref>) that also reported SL genes in A549 and TOV21G cells. Inaccuracies include the annotation of MCF10A as BRCA by Wang and associates (<xref rid="B9" ref-type="bibr">9</xref>) and the annotation of A1847, A2780, C30, CP70, OVCAR5, SKOV3 and UPN275 as OV by Pathak's team (<xref rid="B10" ref-type="bibr">10</xref>). Additionally, in SynLethDB the differences in SL calculation methods are not considered. To address the challenges and knowledge gaps in the SynLethDB, we have developed synthetic lethality knowledge base (SLKB).</p>
    <table-wrap position="float" id="tbl1">
      <label>Table 1.</label>
      <caption>
        <p>Published gene combination double knockout experiments and synthetic lethality (SL) data</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th rowspan="1" colspan="1">Study</th>
            <th rowspan="1" colspan="1">Screening methods</th>
            <th rowspan="1" colspan="1">Study goal</th>
            <th rowspan="1" colspan="1">Cell line(s)</th>
            <th rowspan="1" colspan="1">Number of genes</th>
            <th rowspan="1" colspan="1">SL criteria</th>
            <th rowspan="1" colspan="1">SL data</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td rowspan="1" colspan="1">Wong <italic toggle="yes">et al.</italic> 2016 <italic toggle="yes">(</italic><xref rid="B18" ref-type="bibr">18</xref>)</td>
            <td rowspan="1" colspan="1">CombiGEM-CRISPR (combinatorial genetics en masse) (GeCKOv2 for control)</td>
            <td rowspan="1" colspan="1">identify combinatorial drug targets</td>
            <td rowspan="1" colspan="1">OVCAR8</td>
            <td rowspan="1" colspan="1">160 sgRNAs (3 controls), 23,409 dual sgRNAs, 50 genes, 1,225 gene pairs</td>
            <td rowspan="1" colspan="1">
              <bold>LFC &lt;−0.9, <italic toggle="yes">Q</italic>value &lt;0.01</bold>
            </td>
            <td rowspan="1" colspan="1">52 SL</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Han <italic toggle="yes">et al.</italic> 2017 (<xref rid="B19" ref-type="bibr">19</xref>)</td>
            <td rowspan="1" colspan="1">DrugTarget-CDKO</td>
            <td rowspan="1" colspan="1">generate human gene interaction map + identify combinatorial drug targets</td>
            <td rowspan="1" colspan="1">K562</td>
            <td rowspan="1" colspan="1">205 <bold>genes, 20,791 gene pairs</bold></td>
            <td rowspan="1" colspan="1">SL score &lt;−4</td>
            <td rowspan="1" colspan="1">40 SL</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Shen <italic toggle="yes">et al.</italic> 2017 (<xref rid="B20" ref-type="bibr">20</xref>)</td>
            <td rowspan="1" colspan="1">Combinatorial CRISPR–Cas9</td>
            <td rowspan="1" colspan="1">identify combinatorial drug targets</td>
            <td rowspan="1" colspan="1">HELA, 293T, A549</td>
            <td rowspan="1" colspan="1">266 <bold>sgRNAs, (47 controls), 74,724 dual sgRNAs, 73 genes, 2,628 gene pairs</bold></td>
            <td rowspan="1" colspan="1">SL score &lt;−3</td>
            <td rowspan="1" colspan="1">293T (59 SL), A549 (57 SL), HELA (52 SL)</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Horlbeck <italic toggle="yes">et al.</italic> 2018 (<xref rid="B14" ref-type="bibr">14</xref>)</td>
            <td rowspan="1" colspan="1">CRISPRi</td>
            <td rowspan="1" colspan="1">generate</td>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1">human gene interaction map</td>
            <td rowspan="1" colspan="1">Jurkat, K562</td>
            <td rowspan="1" colspan="1"><bold>1,023 sgRNAs, (18 controls)</bold>,<bold>1,693,897 sgRNAs</bold><bold>(2,088,968 initial), 458 genes (472 initial), up to</bold><bold>111,156 gene pairs</bold></td>
            <td rowspan="1" colspan="1">SL score &lt;−3</td>
            <td rowspan="1" colspan="1">JURKAT (374 SL), K562 (1523 SL)</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Najm <italic toggle="yes">et al.</italic> 2018 (<xref rid="B21" ref-type="bibr">21</xref>)</td>
            <td rowspan="1" colspan="1">Big <bold>Papi (paired aureus and pyogenes for interactions)</bold></td>
            <td rowspan="1" colspan="1">generate human gene interaction map</td>
            <td rowspan="1" colspan="1">876O, A375, A549, HT29, MELJUSO, OVCAR8</td>
            <td rowspan="1" colspan="1">192 <bold>sgRNAs, (42 controls), 52,296 dual sgRNAs, 25 genes, 300 gene pairs</bold></td>
            <td rowspan="1" colspan="1"><italic toggle="yes">Q</italic> value &lt;0.01</td>
            <td rowspan="1" colspan="1">A549 (2 SL), MELJUSO (4 SL), A375 (2 <bold>SL), HT29</bold></td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1">
              <bold>(3 SL), OVCAR8 (4 SL)</bold>
            </td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Zhao <italic toggle="yes">et al.</italic> 2018 (<xref rid="B16" ref-type="bibr">16</xref>)</td>
            <td rowspan="1" colspan="1">Combinatorial CRISPR–Cas9</td>
            <td rowspan="1" colspan="1">understanding metabolic pathways</td>
            <td rowspan="1" colspan="1">
              <bold>HELA, A549</bold>
            </td>
            <td rowspan="1" colspan="1">156 sgRNAs, <bold>23,868 dual sgRNAs, 51 genes, 1,275 gene pairs</bold></td>
            <td rowspan="1" colspan="1">SL score &lt;−3</td>
            <td rowspan="1" colspan="1">A549 (29 SL), HELA (27 SL)</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Ito <italic toggle="yes">et al.</italic> 2021 (<xref rid="B17" ref-type="bibr">17</xref>)</td>
            <td rowspan="1" colspan="1">Digenic CRISPR–Cas9</td>
            <td rowspan="1" colspan="1">understanding digenic dependencies</td>
            <td rowspan="1" colspan="1">HSC5, MeWo, MELJUSO, IPC298, HS936T, HS944T, PATU8988S, PK1, A549, GI1, MEL202</td>
            <td rowspan="1" colspan="1">
              <bold>19,706</bold>
              <bold>sgRNAs (2 controls), 1,219,614 dual sgRNAs, 3,284 genes, 4,859 gene pairs</bold>
            </td>
            <td rowspan="1" colspan="1">False discovery <bold>rate (FDR) &lt; 0.05</bold></td>
            <td rowspan="1" colspan="1">A549 (594 SL), GI1 (476 SL), HS936T (636 SL), HS944T (497 SL), HSC5 (705 SL), IPC298 (619 SL), MEL202 (688 SL), <bold>MELJUSO (547</bold></td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"><bold>SL)</bold>,</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1">MEWO (435 SL), PATU8988S</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1">(618 SL),</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1">PK1 (668 SL)</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Parrish <italic toggle="yes">et al.</italic> 2021 (<xref rid="B15" ref-type="bibr">15</xref>)</td>
            <td rowspan="1" colspan="1">
              <bold>pgPEN (paralog genetic interaction mapping, CRISPR)</bold>
            </td>
            <td rowspan="1" colspan="1">generate human paralog gene interaction map</td>
            <td rowspan="1" colspan="1">PC9, HELA</td>
            <td rowspan="1" colspan="1">9194 <bold>sgRNAs (975 control), 64,573 dual sgRNAs, 2,060 genes, 1,030 gene pairs</bold></td>
            <td rowspan="1" colspan="1">SL score <bold>&lt;−0.5, FDR &lt;0.1</bold></td>
            <td rowspan="1" colspan="1">PC9 (87 SL), HELA (70 SL)</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Diehl <italic toggle="yes">et al.</italic> 2021 (<xref rid="B22" ref-type="bibr">22</xref>)</td>
            <td rowspan="1" colspan="1">Covalently-closed circular-synthesized (3Cs) multiplexing, CRISPR</td>
            <td rowspan="1" colspan="1">understanding autophagy flux</td>
            <td rowspan="1" colspan="1">RPE1</td>
            <td rowspan="1" colspan="1">
              <bold>1,176 sgRNAs (188 controls), 248,191 dual sgRNAs, 200 genes, 10,720 gene pairs</bold>
            </td>
            <td rowspan="1" colspan="1">LFC &lt;−1</td>
            <td rowspan="1" colspan="1">
              <bold>6,776 SL</bold>
            </td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Thompson <italic toggle="yes">et al.</italic> 2021 (<xref rid="B23" ref-type="bibr">23</xref>)</td>
            <td rowspan="1" colspan="1">Combinatorial CRISPR–Cas9</td>
            <td rowspan="1" colspan="1">identify combinatorial drug targets</td>
            <td rowspan="1" colspan="1">
              <bold>A375, MEWO, RPE1</bold>
            </td>
            <td rowspan="1" colspan="1"><bold>13,310 sgRNAs (499 controls)</bold>,<bold>125,514 dual</bold><bold>sgRNAs, 1,680 genes, 1,192 gene pairs</bold></td>
            <td rowspan="1" colspan="1">FDR &lt;0.1</td>
            <td rowspan="1" colspan="1">A375 (44 SL), MEWO (40 SL), RPE (57 SL)</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Tang <italic toggle="yes">et al.</italic> 2022 (<xref rid="B11" ref-type="bibr">11</xref>)</td>
            <td rowspan="1" colspan="1">LentiGuide_DKO, LentiCRISPR_DKO (GeCKOv2 for control)</td>
            <td rowspan="1" colspan="1">identify combinatorial drug targets</td>
            <td rowspan="1" colspan="1">22Rv1</td>
            <td rowspan="1" colspan="1">247 <bold>sgRNAs (25 controls), 48,931 dual sgRNAs, 50 genes, 1,225 gene pairs</bold></td>
            <td rowspan="1" colspan="1">SL <bold>score &lt;−0.361</bold></td>
            <td rowspan="1" colspan="1">274 SL</td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
  </sec>
  <sec sec-type="materials|methods" id="SEC2">
    <title>Materials and methods</title>
    <sec id="SEC2-1">
      <title>Introduction of CRISPR-based gene CDKO experiment</title>
      <p>We recently published the technical details of the design and protocol of our CDKO experiment (<xref rid="B11" ref-type="bibr">11</xref>). Here, we focus on dual single-guided RNA (sgRNA) design and the corresponding data, in which a sgRNA targets either one gene or no gene, i.e. the control sgRNA. Without loss of generalizability, let us assume that the design includes <inline-formula><tex-math id="M0001" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$K$\end{document}</tex-math></inline-formula> control sgRNAs and <inline-formula><tex-math id="M0001a" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$M$\end{document}</tex-math></inline-formula> sgRNAs targeting a single gene. Figure <xref rid="F1" ref-type="fig">1A</xref> presents an overview of a CDKO synthetic lethal screen, in which cells were transfected with a dual-sgRNA library on Day 0. These dual-sgRNAs are sequenced at baseline and again after <italic toggle="yes">T</italic> days of cell culture. Figure <xref rid="F1" ref-type="fig">1B</xref> illustrates that there are <inline-formula><tex-math id="M0002" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$n = {K}^2$\end{document}</tex-math></inline-formula> control dual-sgRNAs. Figure <xref rid="F1" ref-type="fig">1C</xref> shows two types of dual sgRNA targeting one gene. In the first scenario, one control sgRNA and one sgRNA target a gene (<inline-formula><tex-math id="M0003" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$n = 2MK)$\end{document}</tex-math></inline-formula>, and in the second scenario, two sgRNAs target the same gene <inline-formula><tex-math id="M0004" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$( {n = {M}^2} )$\end{document}</tex-math></inline-formula>. Figure <xref rid="F1" ref-type="fig">1D</xref> shows dual sgRNAs targeting two genes. If we consider orientations, <inline-formula><tex-math id="M0005" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$n = 2{M}^2$\end{document}</tex-math></inline-formula> dual sgRNAs are targeting one gene pair.</p>
      <fig position="float" id="F1">
        <label>Figure 1.</label>
        <caption>
          <p>Overview of synthetic lethality (SL) library. <bold>(A)</bold> Design of SL combination gene double knockout (CDKO) experiment. <bold>(B)</bold> Control target sgRNA pairs. <bold>(C)</bold> Single-target sgRNA pairs. <bold>(D)</bold> Dual-target sgRNA pairs.</p>
        </caption>
        <graphic xlink:href="gkad806fig1" position="float"/>
      </fig>
    </sec>
    <sec id="SEC2-2">
      <title>Current CDKO experimental data and data processing methods</title>
      <p>We have identified 11 published CDKO experiments (Table <xref rid="tbl1" ref-type="table">1</xref>). Each study used unique methods of processing and analyzing data to calculate SL scores, thereby creating a significant barrier for comparison of the data. <xref rid="sup1" ref-type="supplementary-material">Supplementary Table S1</xref> summarizes the experiments according to the data processing steps—sgRNA sequencing data filtering, between-sample normalization, normalization on control sgRNAs—and the methods for calculating SL scores. We decided to construct a collection of SL scores based on these published methods, taking into consideration of the methods’ choice of data processing and methods of data analysis, allowing for preservation of some diversity and the retention of several well-established statistical models, such as GEMINI and MAGeCK (<xref rid="B12" ref-type="bibr">12</xref>,<xref rid="B13" ref-type="bibr">13</xref>). We did not attempt to regenerate data analysis methods that were inadequately detailed in the initial publication or shared with a computational software. The methods were evaluated across initial and final timepoint of experiments to lay common ground between calculations. Table <xref rid="tbl2" ref-type="table">2</xref> summarizes these five representative methods: Horlbeck (<xref rid="B14" ref-type="bibr">14</xref>), MAGeCK, GEMINI (<xref rid="B12" ref-type="bibr">12</xref>), median-background/no background (Median-B/NB) and sgRNA derived-background/no background (sgRNA-B/NB). The <xref rid="sup1" ref-type="supplementary-material">Supplementary File presents</xref> a more detailed technical description of these five methods.</p>
      <table-wrap position="float" id="tbl2">
        <label>Table 2.</label>
        <caption>
          <p>Methods of scoring synthetic lethality (SL)</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th rowspan="1" colspan="1">SL scoring approaches</th>
              <th rowspan="1" colspan="1">Filtering</th>
              <th rowspan="1" colspan="1">Normalization</th>
              <th rowspan="1" colspan="1">Processing</th>
              <th rowspan="1" colspan="1">SL calculation method</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">GEMINI score</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">sgRNA counts are normalized to the median of all time points.</td>
              <td rowspan="1" colspan="1">a pseudo-count of 32 is added after normalization.</td>
              <td rowspan="1" colspan="1">variational Bayes: using coordinate ascent variational inference on LFC</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">MAGeCK score</td>
              <td rowspan="1" colspan="1">−</td>
              <td rowspan="1" colspan="1">sgRNA counts are normalized to the median of all time points.</td>
              <td rowspan="1" colspan="1">a pseudo-count of 1 is added before normalization.</td>
              <td rowspan="1" colspan="1">difference between calculated MAGeCK-LFC and single gene MAGeCK-LFC</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Horlbeck score</td>
              <td rowspan="1" colspan="1">Filter sgRNAs with median counts &lt;35</td>
              <td rowspan="1" colspan="1">LFC is normalized to the count ratio between time points.</td>
              <td rowspan="1" colspan="1">a pseudo-count of 10 is added before normalization.</td>
              <td rowspan="1" colspan="1">difference between calculated LFC and quadratic fit of LFC</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Median with background control normalization (Median-B)</td>
              <td rowspan="1" colspan="1">Filter sgRNAs with counts &lt;35 at initial time point</td>
              <td rowspan="1" colspan="1">sgRNA counts are normalized to the median of final time points across single, control, and dual targeting sgRNAs.</td>
              <td rowspan="1" colspan="1">a pseudo-count of 10 is added before normalization.</td>
              <td rowspan="1" colspan="1">difference between calculated LFC and single gene LFCs, normalized to median LFC of controls</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Median without background control normalization (Median-NB)</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">difference between calculated LFC and single gene LFCs<break/></td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">sgRNA-derived SL with background control normalization (sgRNA-B)</td>
              <td rowspan="1" colspan="1">Identical to Median-B/NB</td>
              <td rowspan="1" colspan="1">For each experimental replicate, sgRNA counts are normalized to final time point counts across single, control and dual targeting sgRNAs.</td>
              <td rowspan="1" colspan="1">identical to Median-B/NB</td>
              <td rowspan="1" colspan="1">identical to Median-B, first calculated on sgRNA level then gene level through median</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">sgRNA-derived SL without background control normalization (sgRNA-NB)</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">identical to Median-NB, first calculated on sgRNA level then gene level through median</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
    </sec>
    <sec id="SEC2-3">
      <title>Synthetic lethality knowledge base (SLKB)</title>
      <p><bold>Data:</bold> The synthetic lethality knowledge base (SLKB) built on the 11 SL CDKO experiments (Table <xref rid="tbl1" ref-type="table">1</xref>) stores the sgRNA counts, library sequences and original gene-pair SL scores (Figure <xref rid="F2" ref-type="fig">2A</xref>) of the original CDKO studies, and it implements five scoring algorithms: Horlbeck score (<xref rid="B14" ref-type="bibr">14</xref>), MAGeCK score, GEMINI score (<xref rid="B12" ref-type="bibr">12</xref>), median-background/no background (Median-B/NB) scores, and sgRNA derived-background/no background (sgRNA-B/NB) scores (Supplementary File). Each approach has its own preprocessing steps, is applied to the sgRNA data of every CDKO experiment in the database (Figure <xref rid="F2" ref-type="fig">2B</xref>) and calculates SL scores based on the information in each CDKO library, e.g. guides, targets and/or sequences. For the first time, we assess the impact of SL scoring methods on the identification of synthetic lethality gene pairs.</p>
      <fig position="float" id="F2">
        <label>Figure 2.</label>
        <caption>
          <p>Overview of synthetic lethality knowledge base (SLKB). <bold>(A)</bold> Outline of data curation. <bold>(B)</bold> Outline of analysis pipeline.</p>
        </caption>
        <graphic xlink:href="gkad806fig2" position="float"/>
      </fig>
      <p><bold>Back-end database:</bold> Figure <xref rid="F3" ref-type="fig">3</xref> shows the relational MySQL database housed in the SLKB that contains both the original SL scores and the new scores from seven scoring approaches. The database is accessed by the front-end functions of the SLKB. The available tables can be downloaded both as an SQL (structured query language) dump file and as a CSV (comma separated values) file.</p>
      <fig position="float" id="F3">
        <label>Figure 3.</label>
        <caption>
          <p>Schema of synthetic lethality knowledge base (SLKB). <bold>(A)</bold> Back-end database. <bold>(B)</bold> Joined table of SL score calculation methods.</p>
        </caption>
        <graphic xlink:href="gkad806fig3" position="float"/>
      </fig>
      <p><bold>SLKB front-end functions</bold>: The SLKB is hosted as an R Shiny web application running R v.4.2.1 and Shiny v.1.7.3. The knowledge base includes an overview of the SLKB and the latest updates, a browsing table for SL-pair data for the CDKO studies, a choice of network visualization format, a page for downloading processed and raw data files, a references page and the option of a Venn-diagram comparison of SL pairs across the SLKB scoring approaches. Additionally, the data browsers include a brief description for each study and cell line to aid the selection of SL pairs. The SLKB pipeline, used for knowledge base creation, CDKO data insertion and score calculation, is available as a Python package and can be accessed through SLKB or GitHub.</p>
      <p><bold>Browsing SLKB CDKO experiments:</bold> Users can browse each study in either tabular or network format (Figure <xref rid="F4" ref-type="fig">4</xref>). Both formats provide a study panel to the left that offers users brief descriptions of the CDKO studies and the choice of which studies and cell lines to browse. They can also browse all SL scores available in the SLKB or all cell lines available within a study. A toggle switch on the panel for SL relationships filters the browsed data to significant SL pairs identified by each study. The tabular format allows users to navigate through a table to browse CDKO SL scores and their statistical scores for significance. Users can sort and filter the SL interactions by genes or scores within the table (Figure <xref rid="F4" ref-type="fig">4A</xref>). The network format enables users to search for genes and presents all interactions within the chosen studies and cell lines. Nodes of the networks are colored based on the number of interactions each query gene shares across the query SL network (Figure <xref rid="F4" ref-type="fig">4B</xref>). The tabular format is available under ‘Browse SL Score’ and the network format is available under ‘Browse SL Network’ within the SLKB.</p>
      <fig position="float" id="F4">
        <label>Figure 4.</label>
        <caption>
          <p>Synthetic lethality knowledge base (SLKB) website functionalities (original data). <bold>(A)</bold> Tabular data browsing. SL pairs from Horlbeck <italic toggle="yes">et al.</italic> are illustrated (<xref rid="B14" ref-type="bibr">14</xref>). <bold>(B)</bold> SL network and pair visualization. SL network of <italic toggle="yes">ARL2</italic>, <italic toggle="yes">FAM50A</italic>, <italic toggle="yes">POLD1</italic>, <italic toggle="yes">WDR61</italic> from Jurkat cell line in Horlbeck <italic toggle="yes">et al.</italic> is illustrated.</p>
        </caption>
        <graphic xlink:href="gkad806fig4" position="float"/>
      </fig>
      <p><bold>Browsing SLKB scoring approaches:</bold> Users can browse SLKB-calculated scores by tabular format or interactive Venn diagram presentation (Figure <xref rid="F5" ref-type="fig">5</xref>). Similar to the options for browsing CDKO original scores, each scoring approach includes a study panel that allows users to navigate the desired data sets and a toggle button that permits browsing of significantly SL pairs. The tabular browsing presents all scoring approaches and their statistical scores. As with the options for managing the original scores, users can sort and filter the SL interactions based on their input. Interactive Venn diagrams, on the other hand, permit users to navigate all computed SL interactions and extract overlapping interactions. By default, the top 10% of selected pairs from each approach are visualized along with their respective cutoff scores. Normally, Median-B and sgRNA-B scores are used in the Venn diagram, but Median-NB and sgRNA-NB scores are used if a study has no available dual-targeting controls. The tabular format is available under ‘Query KB’, and Venn diagrams are available under ‘Compare SL Approaches’ within the SLKB.</p>
      <fig position="float" id="F5">
        <label>Figure 5.</label>
        <caption>
          <p>Synthetic lethality knowledge base (SLKB) website functionalities (calculated data). <bold>(A)</bold> Knowledge-base query allows user access to all data within the KB. <bold>(B)</bold> Venn diagrams of SL scoring methods allow users to specify score thresholds for choosing gene pairs.</p>
        </caption>
        <graphic xlink:href="gkad806fig5" position="float"/>
      </fig>
    </sec>
  </sec>
  <sec sec-type="results" id="SEC3">
    <title>Results and discussion</title>
    <sec id="SEC3-1">
      <title>SLKB content</title>
      <p>Table <xref rid="tbl3" ref-type="table">3</xref> summarizes the SLKB content. The knowledge base currently stores the data of 11 CDKO SL studies, which includes counts for 10 of the 11 that were registered to the database. The database houses 3,578,017 sgRNA pair counts and 45,430 sgRNA sequences. Variation of sgRNA libraries across different studies produces varied data. For example, targeting could involve either the SL potential of a specific gene, such as the paralog gene pairs reported by Parrish's team (<xref rid="B15" ref-type="bibr">15</xref>) or pairwise interactions for a set of genes, as reflected on the gene map of Horlbeck and colleagues (<xref rid="B14" ref-type="bibr">14</xref>). The original reported SL scores contained scores for 6,127 unique genes among 280,483 gene pairs, of which 16,059 were found to be synthetic lethal. The 10 CDKO studies with counts yielded 261,958 gene pairs for 6,124 unique genes, and each study and cell line was equipped with five different scoring approaches. We extracted the top 10% of pairs predicted as synthetic lethal from the five main methods and identified a pair as SL only if at least three of the methods agreed on the pair's synthetic lethality, namely the majority vote. The comparison was made between Median-B, sgRNA-derived-B, GEMINI score, Horlbeck score and MAGeCK score. If a study had no dual targeting controls (<xref rid="B16" ref-type="bibr">16</xref>,<xref rid="B17" ref-type="bibr">17</xref>), Median-NB and sgRNA-derived-NB scores were used. Through this agreement, the SLKB contains 13,173 SL interactions and 248,785 non-SL interactions. Majority vote interactions can be downloaded from the SLKB website.</p>
      <table-wrap position="float" id="tbl3">
        <label>Table 3.</label>
        <caption>
          <p>Contents of synthetic lethality knowledge base (SLKB)</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th rowspan="1" colspan="1">Category</th>
              <th rowspan="1" colspan="1">Stored content</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td colspan="2" align="left" rowspan="1">
                <bold>SLKB study reported content</bold>
              </td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">No. of SL CDKO studies</td>
              <td rowspan="1" colspan="1">11 (currently counts available for 10)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">No. of sgRNA guides + sequences</td>
              <td rowspan="1" colspan="1">45,430 sgRNAs (1802 controls)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">No. of sgRNA pair counts</td>
              <td rowspan="1" colspan="1">3,578,017 sgRNA pairs</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">No. of unique genes and gene pairs</td>
              <td rowspan="1" colspan="1">6,127 genes/280,483 gene pairs (148,040 unique)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">No. of SL pairs (originally reported)</td>
              <td rowspan="1" colspan="1">16,059 gene pairs</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">No. of non-SL pairs (originally reported)</td>
              <td rowspan="1" colspan="1">264,424 gene pairs</td>
            </tr>
            <tr>
              <td colspan="2" align="left" rowspan="1">
                <bold>SLKB processed content</bold>
              </td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">No. of unique genes and gene pairs (calculated scores)</td>
              <td rowspan="1" colspan="1">6,124 genes/261,958 gene pairs (127,688 unique)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">No.# of SL pairs (majority vote)</td>
              <td rowspan="1" colspan="1">13,173 gene pairs</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">No. of non-SL pairs (majority vote)</td>
              <td rowspan="1" colspan="1">248,785 gene pairs</td>
            </tr>
            <tr>
              <td colspan="2" align="left" rowspan="1">
                <bold>SL connectivity hubs</bold>
              </td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">No. of SL hub clusters (containing at least 3 genes through SL interactions)</td>
              <td rowspan="1" colspan="1">865</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">No. of giant SL hub clusters (containing &gt;10 genes through SL interactions)</td>
              <td rowspan="1" colspan="1">67</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">No. of mega <bold>SL</bold><bold>hub</bold><bold>clusters (containing &gt;20 genes through SL interactions)</bold></td>
              <td rowspan="1" colspan="1">10</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
    </sec>
    <sec id="SEC3-2">
      <title>SL scoring approaches are highly varied</title>
      <p>The SLKB uses Venn diagrams to compare scoring approaches and run the scoring analyses on every study's cell lines and checking for overlapping pairs reflected substantial variation among scoring approaches. By default, the top 10% of predicted pairs for each algorithm were categorized as synthetic lethal. On average, only 1.21% of the pairs intersected across the five main scoring approaches, and each approach had its own exclusive gene pairs. While exclusive pairs for individual methods were statistically not significant, overlapped pairs among different methods were highly significant (Table <xref rid="tbl4" ref-type="table">4</xref>, binomial distribution test on data of Figure <xref rid="F5" ref-type="fig">5</xref>). Additionally, analysis of pairwise overlapping revealed overlapping rates of Median-B/NB score (50.6%), followed by MAGeCK score (49.31%), sgRNA-derived B/NB score (42.68%), Horlbeck score (27.94%) and GEMINI score (20.94%). Top overlapping scores used log fold change (LFC) as the basis for their score calculation, thus they yielded high overlaps.</p>
      <table-wrap position="float" id="tbl4">
        <label>Table 4.</label>
        <caption>
          <p>Analysis of overlapping synthetic lethal pairs across methods</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th rowspan="1" colspan="1">Comparisons</th>
              <th rowspan="1" colspan="1">Observed overlapping frequency</th>
              <th rowspan="1" colspan="1">Observed overlapping frequency relative frequency among all SL gene pairs <bold>(75,028) (%)</bold></th>
              <th rowspan="1" colspan="1">Observed overlapping relative frequency among all top 10% SL gene pairs <bold>(23,342) (%)</bold></th>
              <th rowspan="1" colspan="1">Expected overlapping frequency</th>
              <th rowspan="1" colspan="1">Enrichment ratio (observed overlapping frequency/ expected overlapping frequency)</th>
              <th rowspan="1" colspan="1"><italic toggle="yes">P</italic>-value</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">All five methods</td>
              <td rowspan="1" colspan="1">192</td>
              <td rowspan="1" colspan="1">0.26</td>
              <td rowspan="1" colspan="1">0.82</td>
              <td rowspan="1" colspan="1">0.75</td>
              <td rowspan="1" colspan="1">256</td>
              <td rowspan="1" colspan="1">1.9e-93</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">GEMINI score vs MAGeCK score</td>
              <td rowspan="1" colspan="1">
                <bold>2,937</bold>
              </td>
              <td rowspan="1" colspan="1">3.92</td>
              <td rowspan="1" colspan="1">12.58</td>
              <td rowspan="1" colspan="1">750</td>
              <td rowspan="1" colspan="1">3.916</td>
              <td rowspan="1" colspan="1">1.9e-93</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">GEMINI score vs Horlbeck score</td>
              <td rowspan="1" colspan="1">
                <bold>1,755</bold>
              </td>
              <td rowspan="1" colspan="1">2.34</td>
              <td rowspan="1" colspan="1">7.52</td>
              <td rowspan="1" colspan="1">750</td>
              <td rowspan="1" colspan="1">2.34</td>
              <td rowspan="1" colspan="1">1.9e-93</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">GEMINI score vs Median-B/NB score</td>
              <td rowspan="1" colspan="1">647</td>
              <td rowspan="1" colspan="1">0.86</td>
              <td rowspan="1" colspan="1">2.77</td>
              <td rowspan="1" colspan="1">750</td>
              <td rowspan="1" colspan="1">0.86</td>
              <td rowspan="1" colspan="1">1</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">GEMINI score vs sgRNA-derived B/NB score</td>
              <td rowspan="1" colspan="1">553</td>
              <td rowspan="1" colspan="1">0.74</td>
              <td rowspan="1" colspan="1">2.37</td>
              <td rowspan="1" colspan="1">750</td>
              <td rowspan="1" colspan="1">0.74</td>
              <td rowspan="1" colspan="1">1</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">MAGeCK score vs Horlbeck score</td>
              <td rowspan="1" colspan="1">
                <bold>1,905</bold>
              </td>
              <td rowspan="1" colspan="1">2.54</td>
              <td rowspan="1" colspan="1">8.16</td>
              <td rowspan="1" colspan="1">750</td>
              <td rowspan="1" colspan="1">2.54</td>
              <td rowspan="1" colspan="1">1.9e-93</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">MAGeCK score vs Median-B/ NB score</td>
              <td rowspan="1" colspan="1">
                <bold>2,080</bold>
              </td>
              <td rowspan="1" colspan="1">2.77</td>
              <td rowspan="1" colspan="1">8.91</td>
              <td rowspan="1" colspan="1">750</td>
              <td rowspan="1" colspan="1">2.77</td>
              <td rowspan="1" colspan="1">1.9e-93</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">MAGeCK score vs sgRNA-derived B/NB score</td>
              <td rowspan="1" colspan="1">
                <bold>2,097</bold>
              </td>
              <td rowspan="1" colspan="1">2.80</td>
              <td rowspan="1" colspan="1">8.98</td>
              <td rowspan="1" colspan="1">750</td>
              <td rowspan="1" colspan="1">2.80</td>
              <td rowspan="1" colspan="1">1.9e-93</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Horlbeck score vs Median-B/NB score</td>
              <td rowspan="1" colspan="1">
                <bold>1,648</bold>
              </td>
              <td rowspan="1" colspan="1">2.20</td>
              <td rowspan="1" colspan="1">7.06</td>
              <td rowspan="1" colspan="1">750</td>
              <td rowspan="1" colspan="1">2.20</td>
              <td rowspan="1" colspan="1">1.9e-93</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Horlbeck score vs sgRNA-derived B/NB score</td>
              <td rowspan="1" colspan="1">
                <bold>2,137</bold>
              </td>
              <td rowspan="1" colspan="1">2.85</td>
              <td rowspan="1" colspan="1">9.16</td>
              <td rowspan="1" colspan="1">750</td>
              <td rowspan="1" colspan="1">2.85</td>
              <td rowspan="1" colspan="1">1.9e-93</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Median-B/NB score vs sgRNA-derived B/NB score</td>
              <td rowspan="1" colspan="1">
                <bold>3,949</bold>
              </td>
              <td rowspan="1" colspan="1">5.26</td>
              <td rowspan="1" colspan="1">16.92</td>
              <td rowspan="1" colspan="1">750</td>
              <td rowspan="1" colspan="1">5.27</td>
              <td rowspan="1" colspan="1">1.9e-93</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">GEMINI score only</td>
              <td rowspan="1" colspan="1">
                <bold>3,532</bold>
              </td>
              <td rowspan="1" colspan="1">4.71</td>
              <td rowspan="1" colspan="1">15.13</td>
              <td rowspan="1" colspan="1">
                <bold>4,921</bold>
              </td>
              <td rowspan="1" colspan="1">0.73</td>
              <td rowspan="1" colspan="1">1</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">MAGeCK score only</td>
              <td rowspan="1" colspan="1">
                <bold>1,995</bold>
              </td>
              <td rowspan="1" colspan="1">2.66</td>
              <td rowspan="1" colspan="1">8.55</td>
              <td rowspan="1" colspan="1">
                <bold>4,921</bold>
              </td>
              <td rowspan="1" colspan="1">0.41</td>
              <td rowspan="1" colspan="1">1</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Horlbeck score only</td>
              <td rowspan="1" colspan="1">
                <bold>3,308</bold>
              </td>
              <td rowspan="1" colspan="1">4.41</td>
              <td rowspan="1" colspan="1">14.17</td>
              <td rowspan="1" colspan="1">
                <bold>4,921</bold>
              </td>
              <td rowspan="1" colspan="1">0.67</td>
              <td rowspan="1" colspan="1">1</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Median-B/NB score only</td>
              <td rowspan="1" colspan="1">
                <bold>2,441</bold>
              </td>
              <td rowspan="1" colspan="1">3.25</td>
              <td rowspan="1" colspan="1">10.46</td>
              <td rowspan="1" colspan="1">
                <bold>4,921</bold>
              </td>
              <td rowspan="1" colspan="1">0.50</td>
              <td rowspan="1" colspan="1">1</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">sgRNA-derived B/NB score only</td>
              <td rowspan="1" colspan="1">
                <bold>2,100</bold>
              </td>
              <td rowspan="1" colspan="1">2.80</td>
              <td rowspan="1" colspan="1">9.00</td>
              <td rowspan="1" colspan="1">
                <bold>4,921</bold>
              </td>
              <td rowspan="1" colspan="1">0.43</td>
              <td rowspan="1" colspan="1">1</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="T4TFN1">
            <p>Note: The null hypothesis is that all five SL calculation methods are independent tests, and the overlapping among their top 10% SL gene pairs are random. An alternative hypothesis is that several SL calculation methods have more enriched overlapping SL gene pairs than their overlapping gene pairs randomly. A binominal distribution is used to calculate the p-value for this enrichment analysis for overlapping gene pairs, <italic toggle="yes">P</italic> value = Prob (<italic toggle="yes">n</italic><inline-formula><tex-math id="M0006" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$ \ge$\end{document}</tex-math></inline-formula> observed overlapping gene pair frequency | <italic toggle="yes">p</italic> = expected gene pair frequency/<italic toggle="yes">N</italic>, <italic toggle="yes">N</italic><bold>= 75,028)</bold>.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
    </sec>
    <sec id="SEC3-3">
      <title>SL connectivity hub</title>
      <p>Although synthetic lethal pairs are very sparse, we identified a pattern in SL interactions among genes (Figure <xref rid="F6" ref-type="fig">6A</xref>): SL hub clusters (i.e. SL interactions across (&gt;2 genes) and SL hub genes (i.e. genes with numerous SL interactions). The SLKB contains 865 SL hub clusters, 67 hub clusters with &gt;10 genes and 10 hub clusters with &gt;20 genes (Table <xref rid="tbl3" ref-type="table">3</xref>) based on the study-reported SL pairs. We believe that SL genes are more likely to be connected with each other than with non-SL genes, but we also observed the separation of many large SL hubs among different SL studies, with sparse SL connections between studies largely attributable to the limited overlap of SL gene sets among SL studies. Owing to lack of experiment validations for top ranked SL gene pairs screened from existing CDKO experiments, currently there is no positive control for the SL and SL connectivity hub.</p>
      <fig position="float" id="F6">
        <label>Figure 6.</label>
        <caption>
          <p>Synthetic lethality (SL) connectivity hub. <bold>(A)</bold> All available SL networks, separated by study. <bold>(B)</bold> Jurkat and K562 SL networks and hubs (Horlbeck <italic toggle="yes">et al.</italic> 2018) (<xref rid="B14" ref-type="bibr">14</xref>).</p>
        </caption>
        <graphic xlink:href="gkad806fig6" position="float"/>
      </fig>
      <p>We also looked into similarities of SL patterns between cell lines when the same gene set was studied (Figure <xref rid="F6" ref-type="fig">6B</xref>). For instance, Horlbeck's study targeted Jurkat and K562 cell lines, and their SL studies shared 378 genes for a total of 458 genes (<xref rid="B14" ref-type="bibr">14</xref>). Despite a reported 374 SL gene pairs in Jurkat cells and 1,523 SL gene pairs in K562 cells, only 82 SL gene pairs overlapped between the two. However, the two cell lines share five of the top 15 hub genes, <italic toggle="yes">ARL2</italic>, <italic toggle="yes">LEO1</italic>, <italic toggle="yes">HUS1</italic>, <italic toggle="yes">MED23</italic> and <italic toggle="yes">WDR61</italic>, suggesting the greater reliability of hub genes as SL network features in understanding the molecular mechanism. Within SLKB, SL gene pairs can be queried against different studies, cell lines and both to assess their conservation across different contexts (Figure <xref rid="F7" ref-type="fig">7</xref>).</p>
      <fig position="float" id="F7">
        <label>Figure 7.</label>
        <caption>
          <p>Sample SL gene pair query under ‘Query KB’ webpage. EZH2, GART, MAPK1, MAPK3 and PIK3C3 genes’ SL connectivity is visualized across <bold>(A)</bold> cell lines and <bold>(B)</bold> studies. Different colors indicate interactions within different cell line and study contexts.</p>
        </caption>
        <graphic xlink:href="gkad806fig7" position="float"/>
      </fig>
    </sec>
  </sec>
  <sec sec-type="conclusions" id="SEC4">
    <title>Conclusion</title>
    <p>Following the latest trends in CRISPR–Cas9 technologies and their performance in the identification of synthetic lethal genes, CDKO studies pave the way for future SL experiments. The SLKB we have developed focuses on the curation of SL data from CDKO studies and presents both original study scores and new SL scores from seven new scoring approaches. To the best of our knowledge, our SLKB is the first SL database that houses all CDKO SL pairs and includes both reported original scores and scores from multiple SL calculation methods. We recognize that different assumptions in methodology generate highly diverse SL scoring approaches, but we observed statistically significant overlap of the top 10% scores across all five approaches. Their overlapped SL gene pairs are more trustworthy than SL gene pairs belonging to an individual SL score calculation method. Median-B/NB score showed the highest overlap (50.6%) with the other approaches. The SLKB offers interactive Venn diagrams that allow users to choose SL pairs that overlap across different scores, and the developed SLKB analysis pipeline is equipped with preprocessing and scoring approaches that permit users to analyze their own CDKO studies. We observed SL hubs and genes that retained their connectivity in different contexts, and users can choose their targets of interest among the available cell lines through these hubs. In the future, the SLKB will continue to curate CDKO SL studies and implement additional scoring approaches where available.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="sup1" position="float" content-type="local-data">
      <label>gkad806_Supplemental_Files</label>
      <media xlink:href="gkad806_supplemental_files.zip">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack id="ACK1">
    <title>Acknowledgements</title>
    <p>The authors thank the research computing services at Ohio Supercomputer Center (OSC) for providing computational resources throughout the study.</p>
  </ack>
  <sec sec-type="data-availability" id="SEC5">
    <title>Data availability</title>
    <p>The SLKB knowledge base and analysis pipelines are both available in the public domain. The SLKB can be freely accessed at <ext-link xlink:href="https://slkb.osubmi.org" ext-link-type="uri">https://slkb.osubmi.org</ext-link>. SLKB's data and pipeline are stored in <ext-link xlink:href="https://doi.org/10.6084/m9.figshare.22902839" ext-link-type="uri">https://doi.org/10.6084/m9.figshare.22902839</ext-link> and <ext-link xlink:href="https://doi.org/10.5281/zenodo.8274172" ext-link-type="uri">https://doi.org/10.5281/zenodo.8274172</ext-link> respectively, under GNU General Public License v.3.0. The documentation can be accessed from <ext-link xlink:href="https://slkb.docs.osubmi.org/" ext-link-type="uri">https://slkb.docs.osubmi.org/</ext-link>.</p>
  </sec>
  <sec id="SEC6">
    <title>Supplementary data</title>
    <p><ext-link xlink:href="https://academic.oup.com/nar/article-lookup/doi/10.1093/nar/gkad806#supplementary-data" ext-link-type="uri">Supplementary Data</ext-link> are available at NAR Online.</p>
  </sec>
  <sec id="SEC7">
    <title>Funding</title>
    <p>Internal funding from The Ohio State University.</p>
    <p><italic toggle="yes">Conflict of interest statement</italic>. None declared.</p>
  </sec>
  <ref-list id="REF1">
    <title>References</title>
    <ref id="B1">
      <label>1.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kaelin</surname><given-names>W.G.</given-names><suffix>Jr</suffix></string-name></person-group><article-title>The concept of synthetic lethality in the context of anticancer therapy</article-title>. <source>Nat. Rev. Cancer</source>. <year>2005</year>; <volume>5</volume>:<fpage>689</fpage>–<lpage>698</lpage>.<pub-id pub-id-type="pmid">16110319</pub-id></mixed-citation>
    </ref>
    <ref id="B2">
      <label>2.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hartwell</surname><given-names>L.H.</given-names></string-name>, <string-name><surname>Szankasi</surname><given-names>P.</given-names></string-name>, <string-name><surname>Roberts</surname><given-names>C.J.</given-names></string-name>, <string-name><surname>Murray</surname><given-names>A.W.</given-names></string-name>, <string-name><surname>Friend</surname><given-names>S.H.</given-names></string-name></person-group><article-title>Integrating genetic approaches into the discovery of anticancer drugs</article-title>. <source>Science</source>. <year>1997</year>; <volume>278</volume>:<fpage>1064</fpage>–<lpage>1068</lpage>.<pub-id pub-id-type="pmid">9353181</pub-id></mixed-citation>
    </ref>
    <ref id="B3">
      <label>3.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cortesi</surname><given-names>L.</given-names></string-name>, <string-name><surname>Rugo</surname><given-names>H.S.</given-names></string-name>, <string-name><surname>Jackisch</surname><given-names>C.</given-names></string-name></person-group><article-title>An overview of PARP inhibitors for the treatment of breast cancer</article-title>. <source>Target Oncol</source>. <year>2021</year>; <volume>16</volume>:<fpage>255</fpage>–<lpage>282</lpage>.<pub-id pub-id-type="pmid">33710534</pub-id></mixed-citation>
    </ref>
    <ref id="B4">
      <label>4.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>J.</given-names></string-name>, <string-name><surname>Wu</surname><given-names>M.</given-names></string-name>, <string-name><surname>Huang</surname><given-names>X.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>L.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>S.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>H.</given-names></string-name>, <string-name><surname>Zheng</surname><given-names>J.</given-names></string-name></person-group><article-title>SynLethDB 2.0: a web-based knowledge graph database on synthetic lethality for novel anticancer drug discovery</article-title>. <source>Database (Oxford)</source>. <year>2022</year>; <volume>2022</volume>:<fpage>baac030</fpage>.<pub-id pub-id-type="pmid">35562840</pub-id></mixed-citation>
    </ref>
    <ref id="B5">
      <label>5.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bragin</surname><given-names>E.</given-names></string-name>, <string-name><surname>Chatzimichali</surname><given-names>E.A.</given-names></string-name>, <string-name><surname>Wright</surname><given-names>C.F.</given-names></string-name>, <string-name><surname>Hurles</surname><given-names>M.E.</given-names></string-name>, <string-name><surname>Firth</surname><given-names>H.V.</given-names></string-name>, <string-name><surname>Bevan</surname><given-names>A.P.</given-names></string-name>, <string-name><surname>Swaminathan</surname><given-names>G.J.</given-names></string-name></person-group><article-title>DECIPHER: database for the interpretation of phenotype-linked plausibly pathogenic sequence and copy-number variation</article-title>. <source>Nucleic Acids Res.</source><year>2014</year>; <volume>42</volume>:<fpage>D993</fpage>–<lpage>D1000</lpage>.<pub-id pub-id-type="pmid">24150940</pub-id></mixed-citation>
    </ref>
    <ref id="B6">
      <label>6.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname><given-names>X.J.</given-names></string-name>, <string-name><surname>Mishra</surname><given-names>S.K.</given-names></string-name>, <string-name><surname>Wu</surname><given-names>M.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>F.</given-names></string-name>, <string-name><surname>Zheng</surname><given-names>J.</given-names></string-name></person-group><article-title>Syn-lethality: an integrative knowledge base of synthetic lethality towards discovery of selective anticancer therapies</article-title>. <source>Biomed. Res. Int.</source><year>2014</year>; <volume>2014</volume>:<fpage>196034</fpage>.<pub-id pub-id-type="pmid">24864230</pub-id></mixed-citation>
    </ref>
    <ref id="B7">
      <label>7.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jerby-Arnon</surname><given-names>L.</given-names></string-name>, <string-name><surname>Pfetzer</surname><given-names>N.</given-names></string-name>, <string-name><surname>Waldman</surname><given-names>Y.Y.</given-names></string-name>, <string-name><surname>McGarry</surname><given-names>L.</given-names></string-name>, <string-name><surname>James</surname><given-names>D.</given-names></string-name>, <string-name><surname>Shanks</surname><given-names>E.</given-names></string-name>, <string-name><surname>Seashore-Ludlow</surname><given-names>B.</given-names></string-name>, <string-name><surname>Weinstock</surname><given-names>A.</given-names></string-name>, <string-name><surname>Geiger</surname><given-names>T.</given-names></string-name>, <string-name><surname>Clemons</surname><given-names>P.A.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Predicting cancer-specific vulnerability via data-driven detection of synthetic lethality</article-title>. <source>Cell</source>. <year>2014</year>; <volume>158</volume>:<fpage>1199</fpage>–<lpage>1209</lpage>.<pub-id pub-id-type="pmid">25171417</pub-id></mixed-citation>
    </ref>
    <ref id="B8">
      <label>8.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bartz</surname><given-names>S.R.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Burchard</surname><given-names>J.</given-names></string-name>, <string-name><surname>Imakura</surname><given-names>M.</given-names></string-name>, <string-name><surname>Martin</surname><given-names>M.</given-names></string-name>, <string-name><surname>Palmieri</surname><given-names>A.</given-names></string-name>, <string-name><surname>Needham</surname><given-names>R.</given-names></string-name>, <string-name><surname>Guo</surname><given-names>J.</given-names></string-name>, <string-name><surname>Gordon</surname><given-names>M.</given-names></string-name>, <string-name><surname>Chung</surname><given-names>N.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions</article-title>. <source>Mol. Cell. Biol.</source><year>2006</year>; <volume>26</volume>:<fpage>9377</fpage>–<lpage>9386</lpage>.<pub-id pub-id-type="pmid">17000754</pub-id></mixed-citation>
    </ref>
    <ref id="B9">
      <label>9.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>X.</given-names></string-name>, <string-name><surname>Fu</surname><given-names>A.Q.</given-names></string-name>, <string-name><surname>McNerney</surname><given-names>M.E.</given-names></string-name>, <string-name><surname>White</surname><given-names>K.P.</given-names></string-name></person-group><article-title>Widespread genetic epistasis among cancer genes</article-title>. <source>Nat. Commun.</source><year>2014</year>; <volume>5</volume>:<fpage>4828</fpage>.<pub-id pub-id-type="pmid">25407795</pub-id></mixed-citation>
    </ref>
    <ref id="B10">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pathak</surname><given-names>H.B.</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Sethi</surname><given-names>G.</given-names></string-name>, <string-name><surname>Hirst</surname><given-names>J.</given-names></string-name>, <string-name><surname>Schilder</surname><given-names>R.J.</given-names></string-name>, <string-name><surname>Golemis</surname><given-names>E.A.</given-names></string-name>, <string-name><surname>Godwin</surname><given-names>A.K.</given-names></string-name></person-group><article-title>A synthetic lethality screen using a focused siRNA library to identify sensitizers to dasatinib therapy for the treatment of epithelial ovarian cancer</article-title>. <source>PLoS ONE</source>. <year>2015</year>; <volume>10</volume>:<fpage>e0144126</fpage>.<pub-id pub-id-type="pmid">26637171</pub-id></mixed-citation>
    </ref>
    <ref id="B11">
      <label>11.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tang</surname><given-names>S.</given-names></string-name>, <string-name><surname>Wu</surname><given-names>X.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>J.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>X.</given-names></string-name>, <string-name><surname>Shao</surname><given-names>S.</given-names></string-name>, <string-name><surname>Gokbag</surname><given-names>B.</given-names></string-name>, <string-name><surname>Fan</surname><given-names>K.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>X.</given-names></string-name>, <string-name><surname>Li</surname><given-names>F.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Generation of dual-gRNA library for combinatorial CRISPR screening of synthetic lethal gene pairs</article-title>. <source>STAR Protoc.</source><year>2022</year>; <volume>3</volume>:<fpage>101556</fpage>.<pub-id pub-id-type="pmid">36060092</pub-id></mixed-citation>
    </ref>
    <ref id="B12">
      <label>12.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zamanighomi</surname><given-names>M.</given-names></string-name>, <string-name><surname>Jain</surname><given-names>S.S.</given-names></string-name>, <string-name><surname>Ito</surname><given-names>T.</given-names></string-name>, <string-name><surname>Pal</surname><given-names>D.</given-names></string-name>, <string-name><surname>Daley</surname><given-names>T.P.</given-names></string-name>, <string-name><surname>Sellers</surname><given-names>W.R.</given-names></string-name></person-group><article-title>GEMINI: a variational Bayesian approach to identify genetic interactions from combinatorial CRISPR screens</article-title>. <source>Genome Biol.</source><year>2019</year>; <volume>20</volume>:<fpage>137</fpage>.<pub-id pub-id-type="pmid">31300006</pub-id></mixed-citation>
    </ref>
    <ref id="B13">
      <label>13.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname><given-names>W.</given-names></string-name>, <string-name><surname>Xu</surname><given-names>H.</given-names></string-name>, <string-name><surname>Xiao</surname><given-names>T.</given-names></string-name>, <string-name><surname>Cong</surname><given-names>L.</given-names></string-name>, <string-name><surname>Love</surname><given-names>M.I.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>F.</given-names></string-name>, <string-name><surname>Irizarry</surname><given-names>R.A.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>J.S.</given-names></string-name>, <string-name><surname>Brown</surname><given-names>M.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>X.S.</given-names></string-name></person-group><article-title>MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens</article-title>. <source>Genome Biol.</source><year>2014</year>; <volume>15</volume>:<fpage>554</fpage>.<pub-id pub-id-type="pmid">25476604</pub-id></mixed-citation>
    </ref>
    <ref id="B14">
      <label>14.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Horlbeck</surname><given-names>M.A.</given-names></string-name>, <string-name><surname>Xu</surname><given-names>A.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>M.</given-names></string-name>, <string-name><surname>Bennett</surname><given-names>N.K.</given-names></string-name>, <string-name><surname>Park</surname><given-names>C.Y.</given-names></string-name>, <string-name><surname>Bogdanoff</surname><given-names>D.</given-names></string-name>, <string-name><surname>Adamson</surname><given-names>B.</given-names></string-name>, <string-name><surname>Chow</surname><given-names>E.D.</given-names></string-name>, <string-name><surname>Kampmann</surname><given-names>M.</given-names></string-name>, <string-name><surname>Peterson</surname><given-names>T.R.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Mapping the genetic landscape of human cells</article-title>. <source>Cell</source>. <year>2018</year>; <volume>174</volume>:<fpage>953</fpage>–<lpage>967</lpage>.<pub-id pub-id-type="pmid">30033366</pub-id></mixed-citation>
    </ref>
    <ref id="B15">
      <label>15.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Parrish</surname><given-names>P.C.R.</given-names></string-name>, <string-name><surname>Thomas</surname><given-names>J.D.</given-names></string-name>, <string-name><surname>Gabel</surname><given-names>A.M.</given-names></string-name>, <string-name><surname>Kamlapurkar</surname><given-names>S.</given-names></string-name>, <string-name><surname>Bradley</surname><given-names>R.K.</given-names></string-name>, <string-name><surname>Berger</surname><given-names>A.H.</given-names></string-name></person-group><article-title>Discovery of synthetic lethal and tumor suppressor paralog pairs in the human genome</article-title>. <source>Cell Rep.</source><year>2021</year>; <volume>36</volume>:<fpage>109597</fpage>.<pub-id pub-id-type="pmid">34469736</pub-id></mixed-citation>
    </ref>
    <ref id="B16">
      <label>16.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhao</surname><given-names>D.</given-names></string-name>, <string-name><surname>Badur</surname><given-names>M.G.</given-names></string-name>, <string-name><surname>Luebeck</surname><given-names>J.</given-names></string-name>, <string-name><surname>Magaña</surname><given-names>J.H.</given-names></string-name>, <string-name><surname>Birmingham</surname><given-names>A.</given-names></string-name>, <string-name><surname>Sasik</surname><given-names>R.</given-names></string-name>, <string-name><surname>Ahn</surname><given-names>C.S.</given-names></string-name>, <string-name><surname>Ideker</surname><given-names>T.</given-names></string-name>, <string-name><surname>Metallo</surname><given-names>C.M.</given-names></string-name>, <string-name><surname>Mali</surname><given-names>P.</given-names></string-name></person-group><article-title>Combinatorial CRISPR-Cas9 metabolic screens reveal critical redox control points dependent on the KEAP1-NRF2 regulatory axis</article-title>. <source>Mol. Cell</source>. <year>2018</year>; <volume>69</volume>:<fpage>699</fpage>–<lpage>708</lpage>.<pub-id pub-id-type="pmid">29452643</pub-id></mixed-citation>
    </ref>
    <ref id="B17">
      <label>17.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ito</surname><given-names>T.</given-names></string-name>, <string-name><surname>Young</surname><given-names>M.J.</given-names></string-name>, <string-name><surname>Li</surname><given-names>R.</given-names></string-name>, <string-name><surname>Jain</surname><given-names>S.</given-names></string-name>, <string-name><surname>Wernitznig</surname><given-names>A.</given-names></string-name>, <string-name><surname>Krill-Burger</surname><given-names>J.M.</given-names></string-name>, <string-name><surname>Lemke</surname><given-names>C.T.</given-names></string-name>, <string-name><surname>Monducci</surname><given-names>D.</given-names></string-name>, <string-name><surname>Rodriguez</surname><given-names>D.J.</given-names></string-name>, <string-name><surname>Chang</surname><given-names>L.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Paralog knockout profiling identifies DUSP4 and DUSP6 as a digenic dependence in MAPK pathway-driven cancers</article-title>. <source>Nat. Genet.</source><year>2021</year>; <volume>53</volume>:<fpage>1664</fpage>–<lpage>1672</lpage>.<pub-id pub-id-type="pmid">34857952</pub-id></mixed-citation>
    </ref>
    <ref id="B18">
      <label>18.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wong</surname><given-names>A.S.L.</given-names></string-name>, <string-name><surname>Choi</surname><given-names>G.C.G.</given-names></string-name>, <string-name><surname>Cui</surname><given-names>C.H.</given-names></string-name>, <string-name><surname>Pregernig</surname><given-names>G.</given-names></string-name>, <string-name><surname>Milani</surname><given-names>P.</given-names></string-name>, <string-name><surname>Adam</surname><given-names>M.</given-names></string-name>, <string-name><surname>Perli</surname><given-names>S.D.</given-names></string-name>, <string-name><surname>Kazer</surname><given-names>S.W.</given-names></string-name>, <string-name><surname>Gaillard</surname><given-names>A.</given-names></string-name>, <string-name><surname>Hermann</surname><given-names>M.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Multiplexed barcoded CRISPR-Cas9 screening enabled by CombiGEM</article-title>. <source>Proc. Natl Acad. Sci. USA</source>. <year>2016</year>; <volume>113</volume>:<fpage>2544</fpage>–<lpage>2549</lpage>.<pub-id pub-id-type="pmid">26864203</pub-id></mixed-citation>
    </ref>
    <ref id="B19">
      <label>19.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Han</surname><given-names>K.</given-names></string-name>, <string-name><surname>Jeng</surname><given-names>E.E.</given-names></string-name>, <string-name><surname>Hess</surname><given-names>G.T.</given-names></string-name>, <string-name><surname>Morgens</surname><given-names>D.W.</given-names></string-name>, <string-name><surname>Li</surname><given-names>A.</given-names></string-name>, <string-name><surname>Bassik</surname><given-names>M.C.</given-names></string-name></person-group><article-title>Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions</article-title>. <source>Nat. Biotechnol.</source><year>2017</year>; <volume>35</volume>:<fpage>463</fpage>–<lpage>474</lpage>.<pub-id pub-id-type="pmid">28319085</pub-id></mixed-citation>
    </ref>
    <ref id="B20">
      <label>20.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shen</surname><given-names>J.P.</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>D.</given-names></string-name>, <string-name><surname>Sasik</surname><given-names>R.</given-names></string-name>, <string-name><surname>Luebeck</surname><given-names>J.</given-names></string-name>, <string-name><surname>Birmingham</surname><given-names>A.</given-names></string-name>, <string-name><surname>Bojorquez-Gomez</surname><given-names>A.</given-names></string-name>, <string-name><surname>Licon</surname><given-names>K.</given-names></string-name>, <string-name><surname>Klepper</surname><given-names>K.</given-names></string-name>, <string-name><surname>Pekin</surname><given-names>D.</given-names></string-name>, <string-name><surname>Beckett</surname><given-names>A.N.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Combinatorial CRISPR-Cas9 screens for de novo mapping of genetic interactions</article-title>. <source>Nat. Methods</source>. <year>2017</year>; <volume>14</volume>:<fpage>573</fpage>–<lpage>576</lpage>.<pub-id pub-id-type="pmid">28319113</pub-id></mixed-citation>
    </ref>
    <ref id="B21">
      <label>21.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Najm</surname><given-names>F.J.</given-names></string-name>, <string-name><surname>Strand</surname><given-names>C.</given-names></string-name>, <string-name><surname>Donovan</surname><given-names>K.F.</given-names></string-name>, <string-name><surname>Hegde</surname><given-names>M.</given-names></string-name>, <string-name><surname>Sanson</surname><given-names>K.R.</given-names></string-name>, <string-name><surname>Vaimberg</surname><given-names>E.W.</given-names></string-name>, <string-name><surname>Sullender</surname><given-names>M.E.</given-names></string-name>, <string-name><surname>Hartenian</surname><given-names>E.</given-names></string-name>, <string-name><surname>Kalani</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Fusi</surname><given-names>N.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Orthologous CRISPR-Cas9 enzymes for combinatorial genetic screens</article-title>. <source>Nat. Biotechnol.</source><year>2018</year>; <volume>36</volume>:<fpage>179</fpage>–<lpage>189</lpage>.<pub-id pub-id-type="pmid">29251726</pub-id></mixed-citation>
    </ref>
    <ref id="B22">
      <label>22.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Diehl</surname><given-names>V.</given-names></string-name>, <string-name><surname>Wegner</surname><given-names>M.</given-names></string-name>, <string-name><surname>Grumati</surname><given-names>P.</given-names></string-name>, <string-name><surname>Husnjak</surname><given-names>K.</given-names></string-name>, <string-name><surname>Schaubeck</surname><given-names>S.</given-names></string-name>, <string-name><surname>Gubas</surname><given-names>A.</given-names></string-name>, <string-name><surname>Shah</surname><given-names>V.J.</given-names></string-name>, <string-name><surname>Polat</surname><given-names>I.H.</given-names></string-name>, <string-name><surname>Langschied</surname><given-names>F.</given-names></string-name>, <string-name><surname>Prieto-Garcia</surname><given-names>C.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Minimized combinatorial CRISPR screens identify genetic interactions in autophagy</article-title>. <source>Nucleic Acids Res.</source><year>2021</year>; <volume>49</volume>:<fpage>5684</fpage>–<lpage>5704</lpage>.<pub-id pub-id-type="pmid">33956155</pub-id></mixed-citation>
    </ref>
    <ref id="B23">
      <label>23.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Thompson</surname><given-names>N.A.</given-names></string-name>, <string-name><surname>Ranzani</surname><given-names>M.</given-names></string-name>, <string-name><surname>van der Weyden</surname><given-names>L.</given-names></string-name>, <string-name><surname>Iyer</surname><given-names>V.</given-names></string-name>, <string-name><surname>Offord</surname><given-names>V.</given-names></string-name>, <string-name><surname>Droop</surname><given-names>A.</given-names></string-name>, <string-name><surname>Behan</surname><given-names>F.</given-names></string-name>, <string-name><surname>Gonçalves</surname><given-names>E.</given-names></string-name>, <string-name><surname>Speak</surname><given-names>A.</given-names></string-name>, <string-name><surname>Iorio</surname><given-names>F.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Combinatorial CRISPR screen identifies fitness effects of gene paralogues</article-title>. <source>Nat. Commun.</source><year>2021</year>; <volume>12</volume>:<fpage>1302</fpage>.<pub-id pub-id-type="pmid">33637726</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
